clique aqui para visualizar o programa final.

Transcrição

7 th LACTRIMS 2012
Latin American Congress of Multiple Sclerosis
5 ANERJ CONGRESS
th
November 28th - 30th • Windsor Barra Hotel
Rio de Janeiro/Brazil
1
LACTRIMS - RIO 2012
PRESIDENT MESSAGE
MStrength.
MScience.
Dear colleagues,
the optic-spinal form of Asiatic Multiple Sclerosis.
We are announcing the FINAL PROGRAM of the
VII LatinAmerican Congress of Multiple Sclerosis,
to be held on 28-30 November 2012, in the city
of Rio de Janeiro. It will gather together in Brazil
the most important Latin-American specialists that
investigate, treat and research Multiple Sclerosis
(MS) and Neuromyelitis Optica (NMO).
The strength of unprecedented
science. The strength of the
MS community. The strength
of our commitment.
In the afternoon, round-table discussions, courses and
oral presentations will be held in four auditoriums.
Three courses of continuous education are
programed. Update in multiple sclerosis for all
health area staff, Methods of epidemiological
research for participants who want to carry out
research, and last but not least, a neuro immunology
course for specialists in demyelinating diseases.
The clinical and laboratorial characteristics of the
Idiopathic Inflammatory Demyelinating Diseases of
the Central Nervous System in the Latin-American
population, the prevalence of these diseases in
different latitudes of the extensive geographical
area, which extends from the frontiers of Mexico
to Patagonia, and the environmental and biological
factors related to this prevalence, will be the main
themes of the Congress. These themes have been
arousing a growing interest in the international
scientific community and will be a part of the
plenary sessions and the round-table discussions
with Latin-American specialists selected for their
scientific production.
We welcome you to the
LACTRIMS Congress 2012.
Visit our booth.
In five Satellite Symposiums, the current and future
treatment of Multiple Sclerosis will be addressed
by Latin-American and European specialists.
More than two hundred original studies have been
accepted for poster or oral presentation. This will
demonstrate the advance of research in poster
sessions and oral presentation, disclosing the
Latin-American experience in research.
LACTRIMS – RIO 2012 will award prizes for the
best works of young researchers and the best
posters. Furthermore, it will award prizes for the
best publications of studies performed in Latin
America between 2010 and 2012.
The program is divided into plenary sessions,
round-table discussions, oral presentations and
sessions for the oral presentation of the posters.
www.genzyme.com
www.msatrium.com
2
The 19 plenary sessions will be held in the morning,
in a single auditorium, with themes about the
current state of knowledge and the characteristics
of MS and NMO in Latin America. These will be
presented by Latin-American specialists who have
been identified for their scientific production. Some
of these specialists work in the USA, Canada and
Europe, where they are the leaders in different fields
of knowledge: Sergio Baranzini (USA), Marcelo
Kremenchutzky (Canada), Raul Mandler (USA), Victor
Rivera (Houston) and Oscar Fernandez (Spain). One
of the speakers on NMO will be Professor Jun-ichiKira
(Japan), who is the most important researcher on
LACTRIMS – RIO 2012 is designed to strengthen
the bonds of friendship between specialists, for
the disclosure of research, and the integration of
groups for the amplification of Latin-American
scientific production in the near future.
Finally a special thanks to all the sponsors
that, ethically and friendly made possible the
organization of this Congress
Regina Maria Papais Alvarenga
Lactrims Congress President
3
ANERJ PRESIDENT MESSAGE
Dear colleagues,
It is with great satisfaction that we are holding our V
of payments. We are sending the boletos for the
Congressof Neurology of Rio de Janeiro, to be held
membership via email for those who have not yet
this year in partnership with the VII Latin-American
made the payment. You can become an associate
Congress of Multiple Sclerosis (7thLACTRIMS), at
or re-register by using the website: www.anerj.
the pleasant and attractive Hotel Windsor Barra
org.br. If you have already paid, please ignore this
on 28,29 and 30 November. Important names from
message.
Brazilian and world neurology will be present at
2222/2012 - nov 2012
Merck Serono:
science that
changes lives
Merck Serono. Over 300 years of tradition,
not only among the professionals in
charge of improving people’s health,
but also among all those who have had
access to its innovating therapies.
Merck Serono’s neurodegenerative
diseases division is working hard
in innovation, and not only for one
biotechnological product showing
our galenic know-how, but rather the
development of new treatment options
and devices, as well as advanced
support services for those stricken with
those diseases. Also considering the
possibilities of scientific development and
improvement for the medical community,
Merck Serono provides several projects
for continued medical education, and
grants incentives for existing educational
projects, publication of scientific papers,
and opportunities for specialization in
major international institutions.
In this important relationship, Merck
Serono is proud of having you as an ally
in the search for a better quality of living
for thousands of patients.
both the Congresses, which I am sure will be of
On Thursday, 29 November, at the end of the day’s
enormous benefit for everyone. Furthermore, we
activities, all the members are invited to our General
must highlight this positive opportunity to meet
Meeting. In this, we will have the opportunity to
again with countless colleagues and friends. This
present, among other points, some results referring
always translates into agreeable and profitable
to the ongoing work of the executive board, which
encounters,
has been achieved through the collaboration of
interchanges,
and
exchanges
of
everyone, great effort and determination. It is
experiences.
important to highlight the situation of our new
As has already been communicated by our Secretary
ANERJ website, with its domain name, hosting
and/or by Interevent, our special partnership,
and password. The website offers several social
associates of ANERJ will have a significant discount
services, for which we rely on your participation.
when they participate in the two Congresses. The
It also provides an excellent opportunity to express
registration should be made through Interevent
all your thoughts. Please send your suggestions on
as quickly as possible. Please remember that
how to improve ANERJ.
this discount is only available to members who
I hope that you all benefit from these two
have paid their 2012 membership. After some
Congresses that ANERJ has the pleasure to offer
important work with Banco Santander, and after
to its associates.
having resolved some outstanding administrative
Merck Serono é uma
divisão da Merck
4
Anúncio 'Merck Neurologia'.indd 1
matters, we are able to offer payment via boleto-
José Mauro Braz de Lima
identificado, which facilitates the work and control
ANERJ President
5
11/8/12 11:24 AM
INDEX
General Information 8
Conference Organization10
International Speakers11
National Speakers13
Map16
Courses18
Overview Programme20
Scientific Program25
ANERJ Scientific Program40
Index 48
Oral Presentation56
6
E- Poster Presentation ANERJ
58
E- Poster presentation LACTRIMS
64
7
GENERAL INFORMATION
Information for Speakers
Organized by
Please bring your presentation to the Speakers Room at least 2 hours before your presentation. Speakers
Room: open from 08:00 AM to 07:00 PM
A technician will assist you in transferring the presentation to a central conference server. When the
transfer is complete, the technician performs a quick run of the presentation in order for you to check
whether the presentation runs correctly and that all parts of the presentation are copied.
Latin-American Committee
for Treatment and Research
in Multiple Sclerosis.
Associação de Neurologia
do Estado do Rio de Janeiro
Conference Secretariat:
Please bring your presentation on CD, DVD or memory stick.
Headsets
Please collect the headset receivers for simultaneous translation at the headset desks located by the
entrances to the session rooms where translation is provided.
Headsets can be returned right after the session or can be kept during the day. Headsets must be
Avenida das Américas, n° 3500 | Sala 405 | Bloco Hong Kong 3000
Barra da Tijuca | Rio de Janeiro | Zipcode: 22640-102
Phone: 55 21 3326 3320 | Fax: 21 2437 1483 | Website: www.interevent.com.br
Venue Address
returned each afternoon before you leave the conference center.
CNA
This congress is certified by CNA - Comissão Nacional de Acreditação.
Participants who are able and registered in CNA and wish to receive the credits should fill at the form at
the conference secretariat.
Score for all specialties: 10 points
Avenida Lucio Costa, n° 2630 | Barra da Tijuca
Rio de Janeiro | Zipcode: 22620-170
Phone: 55 21 2195 5000 | website: www.windsorhoteis.com.br
Badge
The use of the badge will be required in all scientific activities and to access the exhibit area.
There will be 02 categories: prescribers and non-prescribers, so that exhibitors can deliver materials to
Travel Agency
the appropriate category.
Prescribers: doctors and residents
Non-prescribers: other health professionals and students.
Rua Barão de Ipanema, n° 56 - 3° andar
Lost and Found
Copacabana | Rio de Janeiro | Brazil
Found items should be returned to the conference secretariat. If you lose something, please report to
Phone: 55 21 3265 8882 I Fax: 21 2540 8794 I Website: www.bec-eventos.com.br
the conference secretariat for assistance.
8
9
COMMITTEE
LACTRIMS INTERNATIONAL COMMITTEE
Patricio Abad
INTERNATIONAL SPEAKERS
Adriana Carra
Denisa Hurtukova
Alexander Parajeles
Edgard Rojas Huerto
Alina G.quevedo
Edgardo Cristiano
Ana Lucia Rosso
Edgardo Reich
ANERJ COMMITTEE
Andres Villa
Elizabeth Armas
José Mauro Braz de Lima
Arnoldo Soto
Fernando Caceres
Lactrims’s Vice President
Maria Clinete Sampaio Lcativa
Carlos A. Díaz Manzano
Fernando Gracia
Claudia Cárcamo
Antonio Luiz dos Santos Werneck Neto
Carlos Cuevas
Fernando Hamuy Díaz De Bedoya
Carlos Ketzoian
Freda Hernández
Lactrims’s Treasurer
Ana Maria Yamada
Carlos Oehninger
Guillermo Gómez
Fernando Hammuy
Pro Tesoureiro
Marco O Py
Cesar Caparo
Guillermo Izquierdo
Marli Pernes
Christian Naurath
Hans-Peter Hartung
Vocal Titular
Solange Dultra
Claudia Cárcamo
Ibis Soto
Miguel Córdova
Ana Cristina Cabral de Lima
Daniel Amitrano
Jaime Toro
Daniela Pohl
Jenner Velásquez
Darwin Vizcarra
Jill Conners
Vocal Suplente
Orlando Garcea
Lactrims 2012 President
Vocal Suplente
Soniza Vieira Alves Leon
President of the Scientific Committee
Jorge Nogales-Gaete
Lactrims’s President
Miguel Angel Macias
Lactrims’s Secretariat
Violeta Diaz
Fernando Gracia
Vocal Titular
Ana Claudia C B Leite
José Cabrera-Gómez
Vocal Titular
10
11
John Richert
Sergio Baranzini
Jorge Barahona
Silvia Tenembaum
Jorge Correale
Teresa Corona
Jorge Nogales-Gaete
Victor Rivera
Abelardo De Queiroz C. Araújo
Carmen Antão Paiva
Jose A Cabrera Gomez
Violeta Diaz
Adailton Pontes
Celmir De Oliveira Vilaça
Juan Carlos Alcantara
Vladmiro Sinay
Adriano Miranda
Charles Peter Tilbery
Juan Garcia Bonitto
Walter A Rocca
Alberto Alan Gabbay
Cláudia Cristina Ferreira Vasconcelos
Juan Pablo Princich
Yara Ganeo
Alfredo Damasceno
Claudio Heitor Gress
Jun-Ichi Kira
Amilton Antunes Barreira
Cleonice Bento
Lilia Nunez Orozco
Ana Beatriz Calmon Nogueira Da Gama
Cristiana Caires
Liliana Patrucco
Ana Claudia C. Leite
Cristiana Goes
Marcelo Kremenchutzky
Ana Cristina Cabral de Lima
Cristiane Afonso
Mario O. Melcon
Anderson Kuntz Grzesiuk
Cristiane Marins
Mario Rivera Kindel
André Matta
Damácio Ramon Kaimen Maciel
Miguel Angel Macias
Andre Muniz
Daniel Amitrano
Miguel Córdova Ruiz
Angelo Maiolino
Daniel Paes De Almeida Dos Santos
Nancy Richert
Antonio Gomes Neto
Denise Nicaretta
Orlando Garcea
Antonio Luiz Werneck
Denise Sisterolli Diniz
Oscar Fernandez
Arthur Padão Gosling
Doralina Guimarães Brum Souza
Oscar Gonzales Gamarra
Benito Damasceno
Douglas Goodin
Patricio Abad
Bernardo Liberato
Eduardo Davidovich
Pedro Cabello
Bruno Castelo Branco
Eduardo Prezzi
Raul Arcega
Bruno Coutinho
Eliana Maranhão
Raul Mandler
Camila Pupe
Eliasz Engelhardt
Ricardo Buzó
Camila Rodrigues
Elizabeth Batista
Rivera Flores
Carla Quero
Elizabeth Regina Comini Frota
Roberto Rotta Escalante
Carlos Henrique Melo Reis
Elza Dias Tosta da Silva
12
NATIONAL SPEAKERS
13
Emerson Gasparetto
Joseph Brooks
Marleide Gomes
Silvio Pessanha Neto
Ernani Maciel
Leila Chimelli
Marli Pernes
Solange Vianna Dultra
Fabíola Rachid Malfetano
Leonardo de Deus Silva
Marzia P. Sohler
Soniza Vieira Alves Leon
Fernanda Erthal
Leticia Fezer
Maurice Vincent
Soraya Pulier
Fernanda Guimarães
Lucia Fontenelle
Norma Fleming
Suzana Costa Nunes Machado
Fernanda Moll
Luiz Claudio Thuler
Osvaldo Nascimento
Tamara Checcacci
Fernanda Pereira
Luiz Domingos Mendes Melges
Péricles Maranhão-Filho
Tania Regina D. Saad Salles
Fernanda Rueda Lopes
Luiz Felipe Vasconcellos
Palmiro Torrieri Júnior
Tarso Adoni
Fernando Faria De Andrade Figueira
Mônica Koncke Fiuza Parolin
Patricia Beatriz Christino Marinho
Valéria Coelho Santa Rita Pereira
Fernando Mendonça
Marcelo Cagy
Raphael Breder
Yara Dadalti Fragoso
Flavio Henrique De Rezende Costa
Marcio Bezerra
Regina Papais Alvarenga
Verônica Brandão
Gabriel Paiva Da Silva Lima
Marco Antonio Araújo Leite
Renata Paes
Walter Oleschko Arruda
Giseli Quintanilha
Marco Antonio Sales Dantas De Lima
Ricardo Canuto
Greice Cardoso De Carvalho Silva
Marco Oliveira Py
Ricardo Turon
Gustavo Adolfo Rodrigues Valle
Marco Tulio Medina
Rodrigo Barbosa Thomaz
Helcio Alvarenga
Marcos Papais Alvarenga
Rossano Cabral De Lima
Helcio Alvarenga Filho
Marcus Tulius T. Silva
Sebastião Eurico
Helio Teive
Maria Cecília de Vecino
Heloise Helena de Figueiredo Siqueira
Maria Clinete Sampaio Lacativa
Henry Pereira Da Silva
Maria Cristina Del Negro Barroso Freitas
Isabella Guedes
Maria Eugênia Tejada Ocampo
Jefferson Becker
Maria Fernanda Mendes
João Gabriel Dib Farinhas
Maria Lúcia Brito Ferreira
João Santos Pereira
Maria Lúcia Vellutini Pimentel
José Maurício Godoy
Maria Lucia Mendonça
José Vicente Martins
Mariana Spitz
Jose Mauro Braz De Lima
Marina Alvarenga
14
15
MAP
16
17
COURSES
COURSE 01
COURSE 03
Research Methods applied to Multiple Sclerosis
NEUROIMMUNOLOGY OF IDIOPATHIC INFLAMMATORY DEMYELINATING DISEASES
Date: November
28th
Date: November 30th
Time: 14:00pm to 16:00pm
Room: SEGÓVIA II
Room: SEGÓVIA II
Secretary: Juliane Sauter Dalter | Coordenador: CARLOS KETZOIAN
TIME
PROGRAM
Speaker
14:00 - 14:10
Neuroimmunology up to date
Andres Villa
TIME
PROGRAM
Speaker
14:00 - 14:45
Introduction to study design: With examples from multiple sclerosis
Walter A. Rocca
14:45 - 15:15
Acuity of the EM diagnosis in neuroepidemiological studies
Violeta Diaz
14:10 - 14:40
15:15 - 15:45
Capture and recapture application method
Mario O. Melcon
14:40 - 15:10
Neuroimmunology of MS
Jorge Correale
15:45 - 16:15
Studies on risk factors in MS
Luiz Claudio Thuler
15:10 - 15:35
Experimental Allergic Encephalitis
Alessandro Farias
15:35 - 16:00
TH 17
Cleonice Bento
Immunological and pathological features of neuromyelitis optica
COURSE 02
UPDATE - MULTIPLE SCLEROSIS FOR ALL
Date: November 29th
Room: SEGÓVIA II
TIME
PROGRAM
Speaker
14:00 - 14:20
The concept and classification of demyelinating diseases
Fabiola Rachid
14:20 - 14:40
Multiple Sclerosis Diagnostic Criteria
Liliana Patrucco
14:40 - 15:00
Clinical Isolated Syndrome
Roberto Rotta Escalante
15:00 - 15:20
MRI for MS Diagnosis
Emerson Gasparetto
15:20 - 15:40
Inflammation and degeneration in MS
Goodin
15:40 - 16:00
Treatments Algoritms In MS
Carlos Cuevas
18
19
JUN-ICHI KIRA
OVERVIEW PROGRAMME
QUARTA-FEIRA, 28/11/2012
Horário
Segóvia I
Segóvia II
08:00 - 10:00
PLENARY SECTION
09:00 - 10:00
PLENARY SECTION
Segóvia III
Oriente
Movement Disorders
10:00 - 10:30
COFFE-BREAK
10:30 - 11:10
PLENARY SECTION
10:30 - 12:00
The State of the Art in MS
11:10 - 12:30
PLENARY SECTION
Movement Disorders - Part 2
COGNITION
Involuntary Movements : clinic
and botulinum toxin treatment
with ENMG
12:30 - 13:30
12:30 - 14:00
NOVARTIS Satellite Symposium Growing evidence once-daily oral fingolimod in MS
14:00 - 16:00
MS Treatment
Course - Research Methods
applied to MS
Children Demyelinating diseases
16:00 - 16:30
16:30 - 18:30
Segóvia IV - ANERJ
Epilepsy
IIDD in Latin America
Rehabilitation and
Neurophysiology Neuroinfection
COFFEE BREAK
Future MS Treatments
Neuroepidemiology in MS
Genetic and Familiar MS and
MNO
18:30 - 19:30
Opening Symposium - Alcohology
19:00 - 20:30
Simpósio TEVA - Sharpening the Management of MS
QUINTA-FEIRA, 29/11/2012
Horário
Segóvia I
Segóvia II
08:00 - 09:00
Jean Martin Charcot Section
09:00 - 10:00
What is MS And What IS Not MS
10:00 - 10:30
Segóvia III
Oriente
Peripheral Neuropathy and Pain
COFFEE BREAK
Peripheral Neuropathy and Pain
- Part 2
10:30 - 11:10
PLENARY SECTION
10:30 - 12:00
MS in Latin America and Canada
11:10 - 12:30
PLENARY SECTION
12:30 - 14:00
Biogen Idec Symposium : Commitment to Treatments of Demyelinating and Neurodegenerative
Diseases
14:00 - 16:00
Pit Falls in MS Diagnosis
Course - Update MS For All
16:00 - 16:30
16:30 - 18:30
Segóvia IV - ANERJ
Neuropediatrics
Fatigue
Motor Neurone
COFFEE BREAK
Challenges in MS
Update in Methods of
Investigation
Cognition
16:30 - 18:00
Neurommunology
18:00 - 19:00
ANERJ General Assembly
18:30 - 20:00
Simpósio MERCK
20
21
SEXTA-FEIRA, 30/11/2012
Horário
08:00 - 10:00
09:00 - 10:00
10:00 - 10:30
10:30 - 10:50
10:30 - 12:00
Segóvia I
Segóvia II
Segóvia III
Neuromyelitis Optica
Headache
COFFEE BREAK
PLENARY SECTION
Headache - Part 2
PLENARY SECTION
12:30 - 14:00
12:50 - 13:50
Bayer Symposium - Impact of MS on Survival and the Role of Interferon β 1-B
16:00 - 16:30
16:30 - 18:30
18:30 - 19:30
Oriente
PLENARY SECTION
10:50 - 12:30
14:00 - 16:00
Segóvia IV - ANERJ
History of Medicine
Biogen Idec Conference
Hot Topics
Course - Neuroimmunology of IIDD
Advances in Symptomatic
Treatment
Cerebrovascular Diseases
Clinical Trials and Guidelines
Neurointensive Treatment
Latin American Committee
COFFEE BREAK
Helcio Alvarenga Award
Research in IIDD
LACTRIMS Oral Presentation MS
LACTRIMS AND ANERJ CLOSURE SECTION
22
23
Copaxone®:FirstchoiceinMStherapy1
• COPAXONE® Does not interfere with the immunological
surveillance2,3, differing from immunosupressant drugs
that are used in the MS therapy4,8.
• COPAXONE®, Improvement of spasticity can be noted
in the first months of treatment9
• COPAXONE® Increased the Quality of Life by 40% in
treatment-naive patients in the first 6 months of therapy 10
CÓD. ANCO 07.11.12 novembro/2012
QUANTO ANTES MELHOR
11,12
COPAXONE® (acetato de glatirâmer) - solução injetável - uso subcutâneo 20mg/mL - USO ADULTO - Indicações: Reduzir a freqüência de recidivas nos pacientes com esclerose múltipla remissiva recidivante (EMRR). Ainda
não existem estudos comprovando o benefício do COPAXONE® em outras formas de Esclerose Múltipla. Também é indicado no tratamento de pacientes que tiveram um primeiro episódio clínico bem definido e que apresentem alto risco de desenvolver a esclerose múltipla clinicamente definida (EMCD). Contra-indicações: O produto está contra-indicado para pacientes com hipersensibilidade conhecida ao acetato de glatirâmer ou manitol.
Advertências e Precauções: A administração deve ser feita exclusivamente por via subcutânea. Não deve ser administrado por via intravenosa; os pacientes devem ser instruídos sobre técnicas de auto-administração da injeção
de COPAXONE® para garantir a segurança da administração. Baseado nos dados atuais, não é necessário nenhuma precaução especial para pacientes envolvidos em atividades que requerem alerta mental, como dirigir
veículos ou operar máquinas. Como o acetato de glatirâmer pode modificar a resposta imunológica, deve-se considerar a possibilidade de que ele possa interferir com a função imunológica. Gravidez e lactação: Categoria B
de risco na gravidez. Interações medicamentosas: Interações entre o COPAXONE® e outros fármacos não foram completamente avaliadas. Reações Adversas: Reações adversas mais comumente observadas: reações no local
de aplicação, vasodilatação, dor no peito, astenia, infecção, dor, náusea, artralgia, ansiedade e hipertonia. Posologia: a dose recomendada para adultos para o tratamento de esclerose múltipla remissiva recidivante é de 20 mg/
dia injetada subcutaneamente. VENDA SOB PRESCRIÇÃO MÉDICA. Reg. MS 1.5573.0001. Farm. Resp.: Mônica Riyoko Nekozuka – CRF-SP n° 16.970. Teva Farmacêutica Ltda. A persistirem os sintomas, o médico deve
ser consultado. Documentação Científica e informações adicionais estão à disposição da classe médica, mediante solicitação.*CIS: Síndrome Clínica Isolada. Copaxone possui indicação em bula.
Contra-indicações: o produto está contra-indicado para pacientes com hipersensibilidade conhecida ao acetato de glatirâmer ou manitol.
Interações medicamentosas: interações entre o COPAXONE® (acetato de glatirâmer) e outras drogas não foram completamente avaliadas.
Referências: •1.Ministério da Saúde, 2010: DOU 24/09/2010; Portaria nº 493/2010•2.Weber MS, et al. Neurotherapeutics. 2007;4(4):647-653. 2. COPAXONE® prescribing information. Teva Neuroscience, Inc.
•3.Aharoni R et al. PNAS. 2008: 105: 11358-63•4.Mundel T. FTY_AAN May 1, 2009•5.Chun J, et al. Clin Neuropharm. 2010;33(2):91-101.•6.Lopez-Diego RS, et al. Nat Rev Drug Discovery. 2008;7(11):909-920.
•7.Kappos L, et al. N Engl J Med. 2010;362(5):387-401.•8.Cohen JA, et al. N Engl J Med. 2010;362(5):402-415.•9.Jongen P.J., at al. Health-related quality of life in relapsing remitting multiple sclerosis patients
during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health and Quality of Life Outcomes 2010, 8:133.•10. Meca-Lallana JE. Balseiro JJ. Et al. Spasticity improvement
in patients with relapsing-remittingmultiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. J Neurol Sci. 15;315(1-2):123-8.2012.•11. Miller JR. J Manag Care Pharm. 2004; 10(3)(Suppl B):
S4-S11.•12. Mikol DD et al., Lancet Neurol. 2008 Oct;7(10):903-14.
24
LACTRIMS SCIENTIFIC PROGRAM
25
November 28
th
14:00-14:15 -The IIDD spectrum in Latin America
Speaker 1: Regina Alvarenga
14:15-14:30 - IIDD in Central America
Speaker 2: Fernando Gracia
08:00 - 10:00 | Plenary Session
14:30 - 14:45 - IDD in Mexico
ROOM SEGÓVIAS
Speaker 3: Rivera Flores
Chair: Jorge Nogales-Gaete
14:45 - 15:00 - IIDD in Venezuela
Secretary: Suzana Costa Nunes Machado
08:10 - 08:30 - Opening: Latin America
Speaker 4: Ibis Soto
Keynote Speaker: Victor Rivera
15:00 - 15:15 - IIDD in Peru
08:30 - 09:00 - The impact of the published papers: What do they say about Demyelination Inflammatory
Speaker 5: Cesar Caparo
Idiopathic Diseases in Latin America?
15:15 - 16:00 - Oral Presentation
Speaker 1: Regina Papais Alvarenga
15:15 - 15:30 - A 63 - Geographical Distribution of Patients With Multiple Sclerosis treated with
09:00 - 09:30 - MS Prevalence in Latin America
Immunomodulator at Public Healthy System in Chile, 2008-2012
Speaker 2: Mario O. Melcon
Authors: Jorge Elías Nogales-Gaete;Casandra Ivonne Araya Salfate; Claudio Alonso Eloiza Concha; Luis Rodrigo
09:30 - 10:00 - The environmental factors influencing MS immunology mechanism in Latin American
Aracena Conte; María Lorena Acevedo González; Paula Carolina Agurto Merino; Séfora Esperanza Martínez
Speaker 3: Jorge Correale
Espinoza; Sergio Omar Cepeda Zumaeta; Silvia Jazmín Labbé Rojas;Vannia Fernanda Díaz Zamorano.
15:30 - 15:45 - A 62 - Genetic variability in Peruvian patients with relapsing remitting multiple sclerosis,
10:00 - 10:30 | Coffee Break
using STR markers DYS390, DYS391, DYS392 Y chromosome
Authors: Miguel Ernesto Cordova Ruiz
10:30 - 12:00 | Plenary Session - The State of the art in Multiple Sclerosis
15:45 - 16:00 - A 95 - Research Methods applied to Multiple Sclerosis - Neuromyelits Optica and Multiple
ROOM SEGÓVIAS
Sclerosis: a view from DNA, RNA and protein profiles
Chair: Soniza Vieira Alves Leon
Authors:Giselle Penton-Rol;Marcelo Nazabal-Galvez;Hanlet Camacho-Rodríguez;Seydi Pedroso-Santana;Seydi Pedroso-
Secretary: Damácio Ramon Kaimen Maciel
Santana;Majel Cervantes- Llanos; Alberto Cintado- Benítez;Mayte Ale-Martínez;Adelaida Villarreal-Barrios;Tamara
10:30 - 11:00 - Mapping genetic susceptibility and modeling pathogenesis in multiple sclerosis
Díaz-Argudín;Jesus Benítez-Fuentes;Nancy Pavón-Fuentes;Daymet Grass;Jose Antonio Cabrera-Gómez.
Speaker 1: Sergio E Baranzini
Speaker: Mario O. Melcon
11:00 - 11:30 - The role of the Blood Brain Barrier in Multple Sclerosis
Speaker 2: Andres Villa
11:30 - 12:00 - Epidemiology of multiple sclerosis: The need to integrate new approaches to its reality
Speaker 3: Oscar Fernandez
12:30 - 14:00 | Novartis Symposium
Growing evidence once-daily oral fingolimod in MS
ROOM SEGÓVIAS
14:00 - 14:30 | Round Table - Multiple Sclerosis Treatment: Special topics with speakers
defending the agreement or not agreement MS treatment approaches
Fyngolimod - 1st line therapy x 2nd line therapy
ROOM SEGÓVIA I
Chair: Edgardo Cristiano
Secretary: Isabella D´Andrea Meira
14:00 - 14:15 - Fyngolimod 1st line therapy
12:30 - 12:40 | Welcome and introduction
Speaker 1: Orlando Garcea
Speakers: Soniza Vieira Alves Leon & Nadina Frider
12:40 - 13:10 | Scientific paradigms in MS – Burden of disease and unmet needs
Speaker: Jaume Sastre Garriga
13:10 - 13:40 | Growing evidence for the benefit–risk profile of treatment with fingolimod
Speaker: Heinz Wiendl
14:15 - 14:30 - Fyngolimod 2nd line therapy
Speaker 2: Edgardo Cristiano
14:00 - 16:00 | Course - Research Methods applied to Multiple Sclerosis
ROOM SEGÓVIA II
13:40 - 13:55 | Q&A (clinical cases)
Speaker: Soniza & Speakers
Coordinator: Carlos Ketzoian
13:55 - 14:00 | Closing remarks ECTRIMS slides
Secretary: Juliane Sauter Dalter
Speaker: Soniza Vieira Alves Leon
14:00 - 14:45 - Introduction to study design: With examples from multiple sclerosis
Speaker: Walter A Rocca
14:00 - 16:00 | Activities - Idiopathic Inflammatory Demyelinating Diseases (IIDD) in
Latin America
14:45 - 15:15 - Acuity of the MS diagnosis in neuroepidemiological studies
ROOM ORIENTE
15:15 - 15:45 - Capture and recapture application method
Speaker: Violeta Diaz
Chair: Regina Papais Alvarenga
Secretary: Erlane Fernandez
26
27
Speaker: Luiz Claudio Thuler
16:30 - 18:30 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD)
in Latin America
14:00 - 16:00 | Round Table - Children Demyelinating diseases
ROOM ORIENTE
ROOM SEGÓVIA III
Chair: Arnoldo Soto
Chair: Silvia Tenembaum
Secretary: Melina Bernardes
Secretary: Tania Regina D. Saad Salles
16:30 - 16:50 - IIDD in Argentina
15:45 - 16:15 - Studies on risk factors in MS
Speaker 1: Adriana Carra
14:00 - 14:30 - ADEM and NMO in children
16:50 - 17:10 - IIDD in Colombia
Speaker 1: Freda Hernández
Speaker 2: Juan Garcia Bonitto
14:30 - 15:00 - MRI in the differential diagnosis of pediatric demyelinating disorders
17:10 - 17:30 - IIDD in Paraguay
Speaker 2: Juan Pablo Princich
Speaker 3: Fernando Hamuy Díaz de Bedoya and Sara Florentin
15:00 - 15:30 - Pediatric MS
Speaker 3: Daniela Pohl
17:30 - 17:50 - IIDD in Chile
15:30 - 16:00 - Treatment of pediatric demyelinating disorders
Speaker 4: Claudia Cárcamo
Speaker 4: Silvia Tenembaum
17:50 - 18:10 - IIDD in Uruguay
Speaker 5: Carlos Oehninger
Non responders to IFN BETA or Glatiramer Acetate - switch to what?
18:10 - 18:30 - IIDD in Bolivia
ROOM SEGÓVIA I
16:30 - 18:30 | Round Table - Future Multiple Sclerosis Treatments
14:30 - 14:45 - Switch one immunomodulator to other
ROOM SEGÓVIA I
Speaker 6: Maria Eugênia Tejada Ocampo
Chair: Helcio Alvarenga
14:45 - 15:00 - Switch to Natalizumab
Secretary: Vanderson Carvalho Neri
Speaker 4: Rodrigo Barbosa Thomaz
16:30 - 17:00 - Autologus STEM CELL transplantation in MS
Natalizumab x Fingolimode for severe MS
Speaker 1: Amilton Antunes Barreira
ROOM SEGÓVIA I
17:30 - 18:00 - Teriflunomide: Targeting Activated Lymphocyte Proliferation
15:00 - 15:15 - Natalizumab
Speaker 3: Victor Rivera
Speaker 5: Marcos Papais Alvarenga
18:00 - 18:30 - Alemtuzumab: Targeting Circulating Lymphocytes by Selective Depletion
15:15 - 15:30 - Fingolimod
Speaker 4: Guillermo Izquierdo
17:00 - 17:30 - Steam Cell Therapy in Multiple Sclerosis
Speaker 2: Oscar Fernandez
Speaker 6: Jefferson Becker
MS treatment Withdrawal - Is it Possible?
ROOM SEGÓVIA I
16:30 - 18:30 | Round Table - Neuroepidemiology in MS: Latin American Studies
ROOM SEGÓVIA II
Chair: Walter A Rocca
Secretary: Heloise Helena de Figueiredo Siqueira
15:30 - 15:45 - YES!
16:30 - 16:45 - Neuroepidemiology in MS: Infections e MS
Speaker 7: Charles PeterTilbery
Speaker 1: Tereza Corona
15:45 - 16:00 – NO!
16:45 - 17:00 - Association Between The Prevalence of MS And Environmental Factors In Latin America
Speaker 8: Fernando Faria de Andrade Figueira
And The Caribbean: An Ecological Study (GEEMAL: Grupo Colaborativo Multicéntrico para el Estudio
de la Esclerosis Múltiple en América)
16:00 - 16:30 | Coffee Break
Speaker 2: CARLOS KETZOIAN
17:00 - 17:15 - Epidemiological MS in Chile
Speaker 3: Violeta Diaz
28
29
November 29 th
17:15 - 17:30 - Pregnancy and MS
Speaker 4: Yara Dadalti Fragoso
17:30 - 17:45 - Epidemiological MS in Cuba
08:00 - 09:00 | Plenary Session - Jean Martin Charcot Section
Cellebration of Charcot Birthday in November-29 - ANERJ
Speaker 5: Jose A Cabrera Gomez
17:45 - 18:30 Oral Presentation
17:45 - 17:55 - A 16 Breastfeeding and risk of Postpartum Relapses in women with Multiple Sclerosis
ROOM SEGÓVIAS
Authors: Nora Fernández Liguori; Berenice Silva; Diana Klajn;Fernando Cáceres;María Laura Saladino;Orlando Garcea.
Chair: Jose Mauro Braz de Lima
17:55 - 18:05 - A 50 Epidemiology of Multiple Sclerosis in The Island of Margarita, Venezuela
Speaker: Helcio Alvarenga
Authors: Arnoldo Soto; Enrique Ordaz;Evelyn Bracho;Marisol Gallardo;Simon Gomez.
Secretary: Maria Clinete Sampaio Lacativa
18:05 - 18:15 - A 51 Epstein-Barr Virus and Smoking Habits in Brazilian patients with Multiple Sclerosis
Authors: Cátia Silva;Celso Luis Silva Oliveira; Fabio Siquineli;Francisco Tomaz Menezes Oliveira;Heloisa Helena
Ruocco;Joseph Bruno Bidin Brooks;Marcus Vinicius Magno Gonçalves; Sidney Gomes;Sonia Beatriz Felix
Ribeiro;Yara Dadalti Fragoso.
18:15- 18:25 - A 52 Epstein-Barr Vírus Infection of the Central Nervous System and Multiple Sclerosis
Disease Activity
09:00 - 10:00 | Plenary Session - What is Ms And What is Not Ms
ROOM SEGÓVIAS
Chair: Charles PeterTilbery
Secretary: Rodrigo Barbosa Thomaz
Authors: Carlos Otávio Brandão;Adriel dos Santos Moraes;Alessandro S Farias;Alfredo Damasceno;Analeda F
Longhini;Benito Pereira Damasceno;Denise Sayuri Tukada;Felipe Von Glehn; Juan Cabanillas; Leonardo de Deus
09:00 - 09:30 - When one bout and one MRI is MS
Silva;Leonilda M B Santos.
Speaker 1: Jorge Barahona
16:30 - 18:30 | Round Table - Genetic and Familiar MS and MNO in Latin America
ROOM SEGÓVIA III
Chair: Damácio Ramon Kaimen Maciel
09:30 - 10:00 - When one bout and one MRI is not MS
Speaker 2: Soniza Vieira Alves Leon
Secretary: Eduardo Paradella
10:00 - 10:30 | Coffee Break
16:30 - 16:50 - Genetics Studies in Latinamerica
ROOM SEGÓVIAS
Speaker 1: Teresa Corona
10:30 - 12:00 | Plenary Session - MS in Americas
MS in Latin America and Canada
16:50 - 17:10 - Genetics aspects of MS in Brazil
Speaker 2: Soniza Vieira Alves Leon
17:10 - 17:30 - Ancestry information markers application to studies of neurological autoimmune
diseases in admixed population
ROOM SEGÓVIAS
Chair: Teresa Corona
Speaker 4: - Doralina Guimarães Brum Souza
Secretary: Doralina Guimarães Brum Souza
17:30 - 17:50 Familial MS
Speaker 5: Carmen Antão Paiva
10:30 - 10:40 - Natural History MS in Spanish countries
17:50 - 18:10 - Genetics in Colombia
Speaker 1: Liliana Patrucco
Speaker 6: Jaime Toro
10:40 - 11:00 - Natural History MS in Brazil
18:10 - 18:30 - Discusion
Speaker 2: Cláudia Cristina Ferreira Vasconcelos
11:00 - 11:20 - Natural History of Pediatric MS in Latin America
18:30 - 20:30 | TEVA Symposium
Sharpening the Management of MS
Speaker 3: Silvia Tenembaum
11:20 - 12:00 - Natural History MS in Canada
ROOM SEGÓVIAS
Speaker 4: Marcelo Kremenchutzky
18:30 - 18:40 - Welcome and Introduction
Presenter: Soniza Vieira Alves Leon
Speaker: Jill Conners
12:30 - 14:00 | Biogen Idec Symposium : Commitment to Treatments of Demyelinating
and Neurodegenerative Diseases
19:00 - 19:30 - Widening the Glatiramer Acetate Data: The GALA Study
ROOM SEGÓVIAS
18:40 - 19:00 - Importance of Non Biologic Complex Drugs in MS Treatment
Speaker: Robert Zivadinov
19:30 - 19:55 - MS Therapy: Addressing the CNS Pathology
Speaker: Denisa Hurtukova
12:30 - 12:40 - Opening remarks
19:55 - 20:00 - Discussion
12:40 - 13:15 - Tailoring Therapy for the MS Patient: Challenges in Choosing Right Treatment Options
Discussant: Soniza Vieira Alves Leon
Speaker: Hans-Peter Hartung
30
31
13:15 - 13:50 - Biogen Idec Neurology: Current Status of Clinical Development
14:00 - 16:00 | Course - Update - Multiple Sclerosis For All
Speaker: Rick Munschauer
ROOM SEGÓVIA II
13:50 - 14:00 - Closing remarks and Q&A
Chair: Luiz Domingos Mendes Melges
Moderator: Regina Papais Alvarenga
Secretary: Letícia Fezer
14:00 - 14:20 - The concept and classification of demyelinating diseases
14:00 - 16:00 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD)
in Latin America
Speaker: 1: Fabiola Rachid
ROOM ORIENTE
Speaker 2: Roberto Rotta Escalante
Chair: Cláudia Cristina Ferreira Vasconcelos
14:40 - 15:00 - Multiple Sclerosis Diagnostic Criteria
Secretary: Mônica Koncke Fiuza Parolin
Speaker 3: Liliana Patrucco
14:00 - 14:20 - IIDD in Rio Grande do Sul
15:00 - 15:20 - MRI for MS Diagnosis
Speaker: Maria Cecília de Vecino
Speaker 4: Emerson Gasparetto
14:20 - 14:40 - IIDD in Santa Catarina
15:20 - 15:40 - Inflammation and degeneration in MS
Speaker: Suzana Costa Nunes Machado
Speaker 5: Douglas Goodin
14:40 - 15:00 - IIDD in Paraná
15:40 - 16:00 - Treatments Algoritms In MS
Speaker: Mônica Koncke Fiuza Parolin
Speaker 6: Carlos Cuevas
14:20 - 14:40 - Clinical isolated syndrome
14:40 - 15:00 - IIDD in Paraná
Speaker: Walter Oleschko Arruda
14:00 - 16:00 | Round Table
15:00 - 15:20 - IIDD in São Paulo
Fatigue: a MS “Phantom” Symptom
Speaker: Alfredo Damasceno
ROOM SEGÓVIA III
Chair:Maria Fernanda Mendes
Speaker: Luiz Domingos Mendes Melges
Secretary: Debora Sales
14:00 - 14:20 - Fatigue and MS: An Overview
Speaker: Yara Dadalti Fragoso / Maria Sheila Rocha
15:40 - 16:00 - IIDD in Rio de Janeiro
Speaker: Elizabeth Batista, Ana Beatriz Calmon e Maria Lucia Pimentel
14:20 - 14:40 - Fatigue and MRI
Speaker 2: Fernanda Moll / Fernanda Erthal
14:00 - 16:00 | Round Table - Pit Falls in MS Diagnosis
14:40 - 15:00 - Fatigue and disability
ROOM SEGÓVIA I
Speaker 3: Helcio Alvarenga Filho
Chair: Sebastião Eurico
15:00 - 15:20 - Cognition and Mental Fatigue
Secretary: Claudia Rego
Speaker 4: Maria Fernanda Mendes
14:00 - 14:20 - Eritematosous Systemic Lupus Versus MS
15:20 - 15:40 - Physical Intervention, Fatigue and Immunology
Speaker 1: Denise Sisterolli Diniz
Speaker 5: Cleonice Bento
14:20 - 14:40 - Lyme Disease Versus MS
15:40 - 16:00 - Fatigue Treatment
Speaker 2: Maria Lúcia Vellutini Pimentel
Speaker 6: Damácio Ramon Kaimen Maciel
14:40 - 15:00 - Myastenia Gravis and IIDD
Speaker 3: Elza Dias Tosta da Silva
16:00 - 16:30 - Coffee Break
15:00 - 15:20 - Behcet Disease vs MS
Speaker 4: Ernani Maciel
16:30-18:30 | Round Table - Idiopathic Inflammatory Demyelinating Diseases (IIDD) in
15:20 - 15:40 - HAM-TSP Versus Primary Progressive MS
Latin America
Speaker 5: Abelardo de Queiroz C. Araújo
ROOM ORIENTE
15:40 - 16:00 - Hereditary Ataxia vs MS
Chair: Solange Camargo
Speaker 6: Helio Teive
Secretary:Heloise Helene Siqueira
32
33
Speaker 1: Maria Lúcia Brito Ferreira
16:30-18:30 | Round Table - President and Delegates of Latin American Committee of
Research and Treatment in Cognition and Multiple Sclerosis
16:50 - 17:10 - IIDD in Mato Grosso
ROOM SEGÓVIA III
Speaker 2: Anderson Kuntz Grzesiuk
Secretary: Thais Conceição Monteiro
16:50 - 17:10 - IIDD in Mato Grosso
Chair: Benito Damasceno
Speaker 2: Heloise Helena de Figueiredo Siqueira
16:30 - 16:50 - Cognition and MS - Overview
17:10 - 17:30 - IIDD in Goiás
Speaker 1: Miguel Angel Macias
16:30 - 16:50 - IIDD in Pernambuco
16:50 - 17:10 - MS Cognition Studies in Spanish Speaking Latin American Countries
Speaker 3: Denise Sisterolli Diniz
Speaker 2: Fernando Caceres
17:30 - 17:50 - IIDD in Brasília
17:10 - 17:30 - Cognitive Different Pattern In MS According Clinical Types
Speaker 4: Patricia Beatriz Christino Marinho
Speaker 3: Renata Paes
17:50 - 18:10 - IIDD in Minas Gerais
17:30 - 17:50 - Topics on MS and cognition - Experience in Colombia
Speaker 5: Antonio Gomes Neto
Speaker 4: Juan Garcia Bonitto
16:30-18:30 | Round Table - Challenges in MS: Diagnosis and Therapeutic Decisions
ROOM SEGÓVIA I
17:50 - 18:10 - Personality and MS
Speaker 5: Edgardo Reich
18:10 - 18:30 - Cognition and MRI In MS
Chair: Soniza Vieira Alves Leon
Speaker 6: Alfredo Damasceno
16:30 - 17:10 Differential Diagnosis PML in the Setting of MS
Speaker 1: Nancy Richert
18:30 - 20:00 | Merck Symposium
17:10 - 17:30 The Management of Clinical Isolated Syndrome With High Risk to MS Conversion
ROOM SEGÓVIAS
Speaker 2: Darwin Vizcarra
18:30 - 18:40 - Opening
17:30 - 17:50 The Management of Secondary Progressive MS With Active Lesions In MRI
Speaker: Soniza Vieira Alves Leon
Speaker 3: Vladmiro Sinay
18:40 - 19:10 - Optimising Multiple Sclerosis Therapy
17:50 - 18:10 The Management of “Benign” MS
Speaker: Oscar fernandez
Speaker 4: Elizabeth Armas
19:10 - 19:40 - “Multiple Sclerosis - Children’s approach”
18:10 - 18:30 The Management of “Severe” MS?
Speaker: Silvia Tenembaum
Speaker 5: Gutemberg Augusto Cruz dos Santos
16:30-18:30 | Round Table - Update in Methods of Investigation in Multiple Sclerosis
ROOM SEGÓVIA II
Chair: Mauricio Klajenberg.
Secretary: Adriano Miranda
16:30 - 17:00 - The role of advanced MRI techniques in the MS Diagnosis Criteria for Multiple Sclerosis
17:00 - 17:30 - Spinal Cord MRI
Speaker 2: Fernanda Rueda Lopes
17:30 - 18:00 - Electrophysiological Methods
Speaker 3: Joseph Brooks
18:00 - 18:30 - Cerebral Spinal Fluid In MS
Speaker 4: Carlos Oehninger
34
35
November 30 th
14:00 - 16:00 | Round Table - Clinical Trials and Guidelines MS treatment in Latin American
ROOM ORIENTE
Secretary: Valéria Coelho Santa Rita Pereira
08:00 - 10:00 | Plenary Session
14:00 - 14:20 - Brazilian Recommendation for MS treatment: Medical societies X Government
ROOM SEGÓVIAS
Speaker 1: Elza Dias Tosta da Silva
Chair: Jose A Cabrera Gomez
14:20 - 14:40 - MS Guidelines Treatment in Brazil
Secretary: Maria Sheila Rocha
Speaker 2: Suzana Costa Nunes Machado
08:00 - 08:30 - Neuromyelits Optica with recurrent clinical course - A new demyelinating syndrome
14:40 - 15:00 - MS Guidelines in Latin America
Speaker 1: Raul Mandler
08:30 - 09:00 - The relative frequency of NMO and Multiple Sclerosis in Latin American
15:00 - 15:20 - MS Guidelines from LACTRIMS
Speaker 4: Patricio Abad
09:00 - 10:00 - Demyelinating diseases in Asian population
Speaker 3: Jun-Ichi Kira
15:20 - 15:40 - Addressing Natalizumab Therapy related Risks (Globally and Locally)
Speaker 6: John Richert
15:40 - 16:00 - Discussion
10:00 - 10:30 | Coffee Break
14:00 - 16:00 | Session - Hot Topics
ROOM SEGÓVIAS
ROOM SEGÓVIA I
Chair: Antonio Gomes Neto
10:30 - 12:00 | Plenary Section - Neuromyelits Optica in Latin America
Secretary: Paulo Christo
ROOM SEGÓVIAS
14:00 - 14:20 - Chronic cerebro-spinal venous insufficiency
Speaker 1: Leonardo de Deus Silva
Chair: Alberto Alan Gabbay
14:20 - 14:40 - Biological markers in MS - how long we are?
Secretary: Elizabeth Regina Comini Frota
Speaker 2: Elizabeth Regina Comini Frota
10:30 - 11:00 - NMO - Genetic and Epidemiology in Cuba and Martinique
14:40 - 15:00 - Identification of responders and non-responders to immunomoulators
Speaker 1: Jose A Cabrera Gomez
Speaker 3: Valéria Coelho Santa Rita Pereira
11:00 - 11:30 - NMO and Potencial Evoked Visual Test
15:00 - 15:15 - A 74 Inter- And Intragenerational Study Of Ms Familial Cases In A Reference Center In
Speaker 3: Silvio Pessanha Neto
The City Of Rio De Janeiro.
11:30 - 12:00 - MRI pattern in NMO
Authors: Melina da Silva Bernardes;Carmem Lucia Antão Paiva;Cláudia Vasconcelos;Elizabeth Batista;Fernanda
Ferreira Chaves da Costa Pereira; Marcos Papais Alvarenga;Regina Maria Papais Alvarenga;Solange Camargo.
15:15 - 15:30 - A 81 Molecular targets involved in Pathogenesis and Response to Therapy of
12:30 - 14:00 | Bayer Symposium - Impact of MS on Survival and the Role of Interferon 1-B
Demyelinating Diseases
Authors: Majel Cervantes-Llanos;Carmen Valenzuela-Silva;Giselle Pentón-Rol; Gregorio Martínez-Sánchez;Ileana
ROOM SEGÓVIAS
Lopategui-Cabezas;José Cabrera-Gómez; Pedro López-Saura;Ruby Alonso-Ramírez.
12:30 - 12:40 - Introduction
15:30 - 15:45 - A 124 Research of Locus Xq22.3 as transcription source for Endogenous Retrovirus and
Speaker: Marcos Papais Alvarenga
its association with the Multiple Sclerosis Etiology
12:40 - 13:10 - Impact of MS on Survival
Authors: Guilherme Sciascia do Olival;Camila Malta Romano;Charles Peter Tilbery; Laura Sumita;Luis S Nali;Maria
Cristina Domingues Fink;Rodrigo Barbosa Thomaz; Tiago S Faria;Vitor B Cavenaghi;Vitor Serafim.
Speaker:Marcos Papais Alvarenga
15:45 - 16:00 - A 41 Disease modifying therapy withdrawal in relapsing-remitting multiple sclerosis:
13:10 - 13:50 - Interferon β 1-b and Survival
follow-up of 40 patients.
Speaker:Douglas Goodin
Authors: Guilherme Sciascia do Olival; Vitor Breseghello Cavenaghi; Vitor Serafim; Rodrigo Barbosa Thomaz;
13:50 - 13:55 - Q&A
13:55 - 14:00 - Close
36
37
14:00 - 16:00 | Course - Neuroimmunology of Idiopathic Inflammatory Demyelinating
Diseases
16:30 - 18:30 | Round Table - Research in IIDD Latin American Syndromes of NMO
spectrum
ROOM SEGÓVIA II
ROOM SEGÓVIA II
Secretary: Ulisses Cerqueira Linhares
Chair: Jun-Ichi Kira
14:00 - 14:10 - Neuroimmunology up to date
Secretary: Marina Papais Alvarenga
Chair: Andres Villa
14:10 - 14:40 - Immunological and pathological features of neuromyelitis optica
16:30 - 16:50 - Caracteristicas da Neurite Optica nas Síndromes do Complexo NMO
Speaker 1: Jun-Ichi Kira
Speaker 1: Elizabeth Batista
14:40 - 15:10 - Neuroimmunology of MS
16:50 - 17:10 - Brainstein syndrome and encephaloty in NMO
Speaker 2: Jorge Correale
Speaker 2: Marcos Papais Alvarenga
15:10 - 15:35 - Experimental Allergic Encephalitis
17:10 - 17:30 - Positivity frequency of Anti Aqp4 with the Elisa Method in NMO patients treated at the
Speaker 3: Alessandro Faria
Sarah Network – Brasilia Unity
15:35 - 16:00 - The TH17 cell biology in multiple sclerosis and neuromyelitis optica
Speaker 4: Cleonice Bento
Speaker 4: Maria Cristina Del Negro Barroso Freitas
17:30 - 17:50 - Positivity frequency of Anti aqp4 with the Indirect Immunofluorescence Method in
14:00-16:00 | Round Table - Advances in Symptomatic Treatment
Patients With Nmo in São Paulo
ROOM SEGÓVIA III
Speaker 3: Tarso Adoni
Chair: Orlando Garcea
17:50 - 18:10 - A 54 Resting-State Functional Magnetic Resonance Imaging in the assessment of
Secretary: Camila Rodrigues
patients with Neuromyelitis Optica
14:00 - 14:20 - The Neuro rehabilitation is part of symptomatic treatment
Authors: Emerson Leandro Gasparetto; Fabiola Malfetano; Fernanda Cristina Rueda Lopes; Fernanda Miraldi;
Speaker: Fernando Caceres
Isabela Meira; Paulo Roberto Valle Bahia; Romeu Domingues; Soniza Alves-Leon.
14:20 - 14:40 - Bladder and sphincter dysfunction
18:10 - 18:30 - Transverse Myelitis Post Dengue Infection
Speaker: Camila Rodrigues
Speaker 4: Adriano Miranda
14:40 - 15:00 - Spasticity
Speaker: Elizabeth Armas
16:30 - 18:00 | LACTRIMS Oral Presentation MS
15:00 - 15:20 - Sexual Disfunction
Speaker: Fernando Hammuy Díaz de Bedoya
ROOM SEGÓVIA III
15:20 - 15:40 - Ataxia and trembling
Chair: Victor Rivera
Speaker: Orlando Garcea
Secretary: Fabíola Rachid Malfetano
15:40 - 16:00 - Debate
16:30 - 16:40 - A 3 Acute Disseminated Encephalomyelitis: Presentation in the adult population.
16:30 - 18:00 | Activities - President and Delegates of Latin American Committee of
Research and Treatment in Multiple Sclerosis
ROOM ORIENTE
Authors: Guilherme Sciascia do Olival;Camila Malta Romano;Charles Peter Tilbery;Laura Sumita;Luis S Nali;Maria
Cristina Domingues Fink;Rodrigo Barbosa Thomaz; Tiago S Faria; Vitor B Cavenaghi;Vitor Serafim.
16:40 - 16:50 - A 6 Aplication of the Mcdonald 2010 criteria for the diagnosis of Multiple Sclerosis in
an argentinean cohort of patients with clinically isolated syndromes
Coordinator: Jorge Nogales-Gaete
Authors: Liiana Patrucco;Edgardo Cristiano;Juan Ignacio Rojas.
Secretary: Violeta Diaz
16:30 - 16:50 - LACTRIMS - Who are we?
16:50 - 17:00 - A 21 Clinical analysis of Malignant MS in a brazilian reference center for MS
Speaker: Jorge Nogales-Gaete
Authors:Fabrício da Costa Hampshire de Araújo;Cláudia Cristina Ferreira Vasconcelos ;Gutemberg Augusto
16:50 - 17:10 - Groups in Latin American with specific targets: How does it / can it really work?
Cruz dos Santos;Juliana Calvet Kallenbach Aurenção;Regina Maria Papais Alvarenga;Solange Maria das Graças
Speaker: Miguel Córdova Ruiz
Gomes Camargo.
17:10 - 17:30 - A new LACTRIMS
17:00 - 17:10 - A 42 Prognostic factors of Malignant Multiple Scleosis in a cohort of argentinean patients
Speaker: Miguel Angel Macias
Authors: Liliana Patrucco;Edgardo Cristiano;Jimena Miguez;Juan Ignacio Rojas;Verónica Fleitas.
17:10 - 17:20 - A 92 Multiple Sclerosis: natural history and prognostic factors in brazilian patients.
16:30 - 18:30 h | AWARDS
Helcio Alvarenga Awards
Authors: Gutemberg Augusto Cruz dos Santos;Claudia Cristina Ferreira Vasconcelos;Fabrício Hampshire
ROOM SEGÓVIA I
Araujo;Juliana Calvet Kallembach;Luiz Claudio Santos Thuler;Regina Maria Papais Alvarenga;Solange Maria das
Chair: Helcio Alvarenga
Graças Gomes Camargo.
Secretary: Heloise Helena de Figueiredo Siqueira
38
39
17:20 - 17:30 - A 112 Prevalence of Pseudotumoral Demyelinating Lesions in an oncology reference center
Authors: Yasmine Coura Torres; Marco Antônio Sales Dantas Lima; Soniza Vieira Alves Leon.
17:30 - 17:40 - A 11 Brain atrophy as a non response predictor to Interferon? In Relapsing Remitting
Multiple Sclerosis
Authors: Juan Ignacio Rojas;Edgardo Cristiano;Liliana Patucco.
17:40 - 17:50 - A 12 Brain Atrophy evaluation in Multiple Sclerosis Patients: A comparison study with
clinically isolated syndrome and Neuromyelitis Optica
Authors: Fernanda Miraldi Clemente Pessôa;Emerson Leandro Gasparetto;Fernanda Cristina Rueda Lopes;Soniza
Vieira Alves-Leon.
17:40 - 17:50 - A 35 Cytokine profile in Relapsing-Remitting Multiple Sclerosis patients and the
association with the progression and the activity of the disease
Authors: Ana Paula Kallaur;Andréa Name Colado Simão;Damácio Ramon Kaimen-Maciel;Edna Maria Vissoci
Reiche;Elaine Regina Delicato de Almeida;Helena Kaminami Morimoto;Josiane Lopes;Larissa Muliterno
Pelegrino;Renato Marques Andrade;Sayonara Rangel Oliveira;Wildea Lice de Carvalho Jennings Pereira.
18:30-19:30 | Clousure - Hold of the New Lactrims Directors Board and Prize Giving
Ceremony
ROOM SEGÓVIA I
Prizes will be given to the following categories
1. Best Latin American
published papers between 2010 and 2012
2. Best posters presented in 7th LACTRIMS-RIO
3. Best posters presented for young researchers in 7th LACTRIMS - RIO
4.Best posters presented in 5th Congress of ANERJ
5. Best works submitted by students in LACTRIMS/ANERJ - HELCIO ALVARENGA AWARD
ANERJ SCIENTIFIC PROGRAM
40
41
November 28 th
08:00 - 09:00 | Plenary Session - V Anerj Congress – Lactrims Plenary
ROOM SEGÓVIAS
12:30 - 13:30 | V Anerj Congress - Symposium
Video-conference: Involuntary Movements: clinic and botulinum toxin treatment
with ENMG
ROOM SEGÓVIA IV
Moderator: Denise Nicaretta
Speakers: Ana Lucia Rosso, Flavio Henrique de Rezende Costa
08:10 - 08:30 - Opening
Speaker 1: Victor Rivera
08:30 - 09:00 - The impact of the published papers: What do they say about Demyelination Inflammatory
Idiopathic Diseases in Latin America?
14:00 - 16:00 | Round Table - V Anerj Congress - Epilepsy thoughout life
ROOM SEGÓVIA IV
Secretaty: Yara Ganeo
Moderator: Cristiane Marins
09:00 - 10:00 | Round Table - V Anerj Congress - Movement Disorders
ROOM SEGÓVIA IV
14:00 - 14:40 - Neonatal and breastfeeding
Speaker: Lucia Fontenelle
14:40 - 15:20 - Kindergarten and Grammar School
Secretary: Celmir de Oliveira Vilaça
Speaker: Gustavo Adolfo Rodrigues Valle
Moderator: Luiz Felipe Vasconcellos
09:00 - 09:20 - Cognitive alterations in Parkinson’s Disease
Speaker: Raphael Breder
09:20 - 09:40 - Sleep disfunctions in Parkinson’s Disease
Speaker:João Santos Pereira
09:40 - 10:00 - Coréias: Differential diagnostic
15:20 - 16:00 - Teenager and Adult
Speaker: Cristiane Afonso
16:00 - 16:30 | Coffee Break
16:30 - 17:30 | Round Table - V Anerj Congress - Rehabilitation and Neurophysiology
Speaker: Mariana Spitz
ROOM SEGÓVIA IV
Secretaty: Fernanda Guimarães
10:00-10:30 | Coffee Break
Moderator: José Vicente Martins
10:30 - 11:10 | Round Table - V Anerj Congress - Movement Disorders
ROOM SEGÓVIA IV
16:30 - 16:50 - Miofascial pain
Speaker: Palmiro Torrieri Júnior
16:50 - 17:10 - Chronic Lumbar pain
10:30 - 10:50 - Tiques - Up to date
Speaker: Verônica Brandão
Speaker: Marco Antonio Araújo Leite
17:10 - 17:30 - Neuropathic pain
10:50 - 11:10 - Demyelinating Diseases and Movement disfunctions
Speaker: Artur Padão Gosling
Speaker: Osvaldo JM Nascimento
17:30 - 18:30 | Round Table - V Anerj - Neuroinfection
11:10 - 12:30 | Round Table - V Anerj Congress - Cognition
ROOM SEGÓVIA IV
ROOM SEGÓVIA IV
Secretary: Ricardo Canuto
Secretary: Denise Nicaretta
Moderator: Marzia P. Sohler
Moderator: Tamara Checcacci
17:30 - 18:00 - Neurological manifestations of encephalitis
11:10 - 11:30 - Alzheimer 2011
Speaker: Marcus Tulius T. Silva
Speaker: Ana Cristina Cabral de Lima
18:00 - 18:30 - Neuroimage in encephalitis
11:30 - 11:50 - Dementia with Lewy bodies
Speaker: Isabella Guedes
Speaker: Luiz Felipe Vasconcellos
18:30 - 19:30 | Opening Symposium - V Anerj Congress - Alcoholism Perspective in
Public Health
11:50 - 12:10 - Mixed Dementia
Speaker: Eliasz Engelhardt
12:10 - 12:30 - Cognitive vascular impairment in sickle cell disease
Speaker: Ana Claudia C. Leite
42
ROOM SEGÓVIA IV
Speaker: Jose Mauro Braz de Lima
43
November 29 th
14:00 - 14:20 - Genetic contribution in ELA
Speaker: Pedro Cabello
14:20 - 14:40 - Epidemiologic aspects of ELA in Latin America
08:00 - 09:00 | Plenary Session - Jean Martin Charcot Section
Cellebration of Charcot Birthday in November-29 - ANERJ
Speaker: Carlos Ketzoian
14:40 - 15:00 - Epidemiologic aspects of ELA in Brazil / Rio de Janeiro
Speaker: Marli Pernes
ROOM SEGÓVIAS
15:00 - 15:20 - Conventional Magnetic resonance and advanced image in the diagnosis of ELA. What
are the main data?
Speaker: Helcio Alvarenga, Jose Mauro Braz de Lima
Speaker: Isabella Guedes
09:00 - 10:00 | Round Table - V Anerj Congress - Peripheral Neuropathy and pain Neuropathies of fine fibers / Neuropathic pain
15:20 - 15:40 - ELA - Syndrome or disease – The Nosological limits
Speaker: Jose Mauro Braz de Lima
15:40 - 16:00 - Debate
ROOM SEGÓVIA IV
Secretary: João Gabriel Dib Farinhas
16:00 - 16:30 | Coffee Break
Moderator: Giseli Quintanilha
09:00 - 09:20 - Pain: Central and peripheral sensitivity – the role of the glial cell
Speaker: André Matta
16:30 - 18:00 | Conference - V Anerj Congress - Neuroimmunology
How many MS patients are there in the State of Rio de Janeiro?
09:20 - 09:40 - Electroneuromyography in pain?
ROOM SEGÓVIA IV
Speaker:Eduardo Davidovich
Secretary: Marina Alvarenga
09:40 - 10:00 - Automatic evaluation
Moderator: Cláudia Cristina Ferreira Vasconcelos
Speaker: Bruno Coutinho
16:30 - 16:40 - Prevalence study on MS in the city of Rio de Janeiro
Speaker: Maria Clinete Sampaio Lacativa
10:00 - 10:30 | Coffee Break
16:40 - 16:50 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Federal
10:30 - 11:10 | Round Table - V Anerj Congress - Peripheral Neuropathy and Pain – Part 2
da Lagoa
Speaker: Marcos Papais Alvarenga
ROOM SEGÓVIA IV
16:50 - 17:00 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Federal
10:30 - 10:50 - Painful peripheral Neuropathies
dos Servidores do Estado
Speaker: Camila Pupe
Speaker: Marcelo Cagy
10:50 - 11:10 - New evaluation instruments for fine fiber neuropathies
17:00 - 17:10 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Clementino
Speaker: Osvaldo JM Nascimento, Bruno Coutinho
Fraga Filho
11:10 - 12:40 | Round Table - V Anerj Congress - Neuropediatrics
Speaker: Fabiola Rachid
17:10 - 17:20 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Santa Casa de
ROOM SEGÓVIA IV
Misericórdia
Secretary: Carla Quero
Speaker: Leticia Fezer
Moderator: Tania Regina D. Saad Salles
17:20 - 17:30 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Hospital Pedro
11:10 - 11:40 - Perinatal inflammation: Implications for Neurological and Neuropsychiatric diseases in childhood
Ernesto
Speaker:Adailton Pontes
Speaker: José Maurício Godoy
11:40 - 12:10 - Asperger Syndrome X Autistic Specter
17:30 - 17:40 - Data on MS prevalence in patients in the city of Rio de Janeiro at the Ordem Terceira
Speaker: Rossano Cabral de Lima
da Penitência
12:10 - 12:40 - Learning disorders – It is not always ADHD
Speaker: Fernando Figueira
Speaker: Solange Vianna Dultra
17:40 - 17:50 - MS Prevalence study in the Sul Fluminense Region
14:00 - 16:00 | Round Table - V Anerj Congress - Motor Neurone
ROOM SEGÓVIA IV
Speaker: Ana Beatriz Calmon Nogueira da Gama
17:50 - 18:00 - Data on MS prevalence studies in patients in the city of Volta Redonda
Speaker: Fernanda Pereira
Secretary: Claudio Heitor Gress
Moderator: Carlos Henrique Melo Reis
18:00 - 19:00 | General Assembly Anerj
44
45
November 30 th
ROOM SEGÓVIA IV
12:20 - 12:50 - Who’s Who?
Speaker: Péricles Maranhão-Filho
08:00 - 09:00 | PLENARY SESSION - V Anerj Congress - Lactrims Plenary
Chair: Jose A Cabrera Gomez
12:50 - 13:50 | imposium Biogen IDEC - Progressive Multifocal
Leucoencephalopathy in MS patients
Secretary: Maria Sheila Rocha
ROOM SEGÓVIA IV
08:00 - 08:30 - Neuromyelits Optica with recurrent clinical course - A new demyelinating syndrome
Chair: Marcelo Cagy
Speaker:Raul Mandler
Speaker: Gabriel Paiva da Silva Lima
ROOM SEGÓVIAS
08:30 - 09:00 - Multiple Sclerosis and Neuromyelitis Optica in Caribbean Population
Speaker: José A. Cabrera Gomez
14:00 - 16:00 | Round Table - V Anerj - Cerebrovascular Diseases
Severe Phase Ischemic Cva
09:00 - 10:00 | Round Table - V Anerj Congress - Headache
ROOM SEGÓVIA IV
ROOM SEGÓVIA IV
Secretary: Eduardo Prezzi
Secretary: Greice Cardoso de Carvalho Silva
Moderator: Marco Oliveira Py
Moderator: Eliana Maranhão
14:00 - 14:45 - Debate: Trombolisis beyond 4,5 hours (pros and cons)
09:00 - 09:20 - Migraine aura
Speaker: Henry Pereira da Silva
Speaker: Maurice Vincent
14:00 - 14:45 - Debate: Trombolisis beyond 4,5 hours (pros and cons)
09:20 - 09:40 - Migraine and cerebellum
Speaker: Soraya Pulier
Speaker: Cristiana Goes
14:45 - 15:30 - Debate: Decompressive craniectomy beyond 60 years (pros and cons)
09:40 - 10:00 - Migraine and vertigo
Speaker: Christian Naurath
14:45 - 15:30 - Debate: Decompressive craniectomy beyond 60 years (pros and cons)
Speaker: Daniel Paes de Almeida dos Santos
10:00 - 10:30 | Coffee Break
15:30 - 16:00 - Diffusion allied to perfusion in severe ischemia
Speaker: Cristiana Caires
10:30 - 10:50 | Round Table - V Anerj Congress - Headache - Part 2
16:00 - 16:30 | Coffee Break
ROOM SEGÓVIA IV
10:30 - 10:50 - Migraine and SAF
16:30 - 18:00 | Round Table - V Anerj Congress - Neurointensive Treatment
Speaker: Norma Fleming
ROOM SEGÓVIA IV
10:50 - 12:30 | Round Table - V Congresso da ANERJ - History of Medicine
Secretary:Daniel Amitrano
ROOM SEGÓVIA IV
Moderator: Bruno Castelo Branco
Secretary: Cristiana Goes
16:30 - 16:50 - Vasospasm in HSA – New techniques and treatment
Moderator: Maria Clinete Sampaio Lacativa
Speaker: Bernardo Liberato
10:50 - 11:20 - Art in Neurology
16:50 - 17:10 - The role of the EEG in the Neurointensive care unit
Speaker:
Speaker: Maria Lucia Mendonça
10:50 - 11:00 - In Litterature
17:10 - 17:30 - Hypothermia. When and what to do?
Speaker: Maria Clinete Sampaio Lacativa
Speaker: Ricardo Turon
11:00 - 11:10 - In Music
17:30 - 17:50 - Cranioencephalic Trauma
Speaker: Antonio Luiz Werneck
Speaker: Fernando Mendonça
11:10 - 11:20 - In painting and sculpture
17:50 - 18:00 - Debate
11:20 - 11:50 - Charles David Marsden and the functional anatomy of the base lymph nodes
18:00-19:00 | CLOSURE
Speaker: Antonio Luiz Werneck
V Anerj Congress - Closure
11:50 - 12:20 - The common origin of teaching practice of mental and neurological diseases in Brazil
ROOM SEGÓVIA IV
Speaker: Marleide Gomes
46
47
INDEX AUTHORS
Castillo, M.A 77
Benítez-Fuentes, J.A 95
Catarino, A.A 38
Bento, C. A 169; A 97
Cavenaghi, V.A 124; A 101; A 41
AUTHORS
Bermudez, J.A 101; A 33
ABSTRACTS
Ceragioli, H.A 165
Andres VillaA 99
Bernardes, M.A 38; A 74
Abib, C.A 25
Cerqueira, D.A 29; A 30
Apostolos, S.A 101
Adoni, T.A 83
Araújo, F.A 21; A 92; A 30
Agostinho, L.A 9; A 10
Besada, C.A 14; A 61
Boyko, A.A 129
Cervantes- Llanos, M.A 95; A 76; A 81
Christo, P.A 135; A 28; A 47; A 93; A 5
Araújo, N.A 30
Bracho, E.A 50
Aguero, F.A 83
Cintado- Benítez, A.A 76; A 95
Arbildi, M. A 158
Brandão, C.A 89; A 52
Albuquerque, L.A 137; A 152
Claudino, R.A 83
Arelis, A.A 110; A 163; A 27
Brito, C.A 49
Alcántara, J. A 158
Clemente, H. A 107
Arias, E.A 125
Armas, E.A 127; A 146
Brooks, J.A 126;A 138;A 2;A 51;A 83;
A 137
Cohen, J.A 90
Arnold, D.A 46
Brucki, S.A 153;A 20
Comini-Frota, E.A 138; A 83; A 137
Arruda, W.A 137; A 138; A 83
Brum, D.A 155
Concha, C.A 119; A 120; A 121; A 63; A 122
Arzuaga, A.A 76
Buzó, R. A 158
Conte, L.A 119; A 120; A 121; A 63
Aurenção, J.A 21
Cabanillas, J.A 52
Conte, R.A 122
Ávalos, J.A 7
Cabral, F.A 144
Cores, E.A 100; A 99
Aviña, G.A 45
Caceres, F.A 85
Azevedo, L.A 117; A 56; A 70
Cáceres, F.A 16;A 48
Cores, V.A 8
Correa, E.A 83; A 138
Bahia, P.A 132; A 4; A 54
Correale, J.A 160; A 90; A 34; A 98; P 3
Banwell, B.A 129
Cal, H.A 31
Calabresi, P.A 161
Baptista, S.A 36; A 40; A 58; A 83; A 96
Callegaro, D.A 160;A 101;A 128;A 33
Cossío, M.A 95
Barahona, J. Calvet, J.A 37
Costa, J.A 134
Calzadilla, L.A 91
Costa, M.A 113
Camacho-Rodríguez, HA 95
Couto, R.A 115; A 84
Camargo, S.A 140;A 37;A 89;A 49;A 74;
A 136;A 21;A 30;A 92;A 38
Cristiano, E.A 160; A 11; A 13; A 14; A 15;
A 42; A 6; A 61; A 78
Camilo, D.A 165
Cruz, A.A 108
Campanella, L.A 140; A 65
Cruz, E.A 116; A 77
Carneiro, M. A 156
Carolino,F.A 72
Cruz, L.A 150
Batista, E.A 140; A 37; A 26; A 38;
A 89; A 74
Carrá, A.A 83; A 143; A 75; A 43
Cúneo, J.A 48
Becker, J.A 137
Carrasco, J.A 119; A 122
Curbelo, C. A 143; A 75; A 43
Beckmann, K.A 131
Carvalho, M.A 137; A 138
Cutter, G.A 131
Benedict, R.A 85
Carvalho, S.A 86; A 32
Damasceno, A.A 83; A 52
Ale-Martínez, M.A 95
Alfieri, D.A 148
Almeida, E.A 148; A 35
Almeida, S.A 36; A 40; A 58; A 83
Alonso, R.A 3
Alonso-Ramírez, R.A 81
Alvarenga Filho, H.A 86; A 107; A 130;
A 32
Alvarenga, H.
A 140; A 37;A 72;A 140;
A 1;A 38;A 89;
A 97;A 49;A 65;
A 74; A 171
Correia, F.A 91
Alvarenga, M.A 1; A 97; A 38
Alvarenga, R.A 72; A 139; A 140; A 37;
A 86; A 32; A 26; A 109;
A 103; A 106; A 111;
A 113; A 114; A 133;
A 136; A 151; A 66; A 89;
A 90; A 97; A 21; A 29;
A 30; A 49; A 57; A 65;
A 66; A 74; A 88; A 92;
A 107; A 1; A 38; A 171;
P 1; P 15;
P8
Baranauskas, V.A 165
Baranzini, S. P4
Barbosa, A.A 56
Barkhof, F.A 161; A 44
Alves, L.A 25
Bar-Or, A.A 161; A 24; A 46; A 59
Alves-Leon, S.A 144; A 54; A 55; A 112;
A 10; A 58; A 88 ; A 96;
A 134; A 138; A 36; A 40;
A 12; A 83; A 9; A 164;
P 9; A 171
Barreira, A.A 155; A 170
Bastos, A.A 117; A 70
Cukierman, E.A 103; A 66
Andrade, H.A 153
Andrade, P.A 19
Andrade, R.A 148; A 35; A 104; A 115; A
84
48
49
A 83; A 126
Kerszberg, M.A 125
González, M.A 119; A 120; A 121; A 63;
A 122
Kira, J. A 168; P 16
Fiorentini, L.A 8
Fleitas, V.A 118; A 15; A 42
Gonzalo, H.A 79
Florentin, S.A 118; A 24; A 46; A 59
Goodin, D.A 131
Fragoso, Y.A 126; A 137; A 138; A 40; A 2;
A 51; A 83; A 36; A 17; A 18
Gracia, F.A 160
Damasceno, B.A 17; A 18; A 52
Fiore, A.A 83
Dawson, K.A 24; A 46; A 59
Kirchmeyer, C.A 57; A 29
Defanti, I.A 53
Klajn, D.A 16
Deslandes, M.A 37
Kosac, V.A 31; A 67
Dias, R.A 86; A 32
Díaz, E.A 83
Kremenchutzky, M.A 131; P 13
Grass, D.A 95
Krupp, L.A 129
Franco, C.A 83
Díaz-Argudín, T.A 95
Grzesiuk, A.A 141; A 83
Kuperman, G.A 48; A 145
Freedman, M.A 44
Diniz, D. A 156
Guerreiro, C.A 155
Kurukulasuriya, N.A 24; A 59; A 46
Lacativa, M.A 88
Freitas, M.A 102; A 142
Domingues, R.A 132; A 4; A 54; A 134
Guerrero, M.A 23
Doring, T.A 144; A 55; A 132; A 4
Frider, N.A 160; A 90; A 34
Ebers, G.A 131
Friedreich, A.A 117
Guiu, B.A 79
Lagumersindez-Denis, NA 76
Gumieiro, B.A 141
Gallardo, M. A 105; A 50; A 64
Gama, P.A 137; A 138
Edan, G.A 44
Eizaguirre, B.A 100; A 99
Langdon, D.A 131
Gutfilen, G. A 55
Lanius, V.A 44
Hartung, H.A 44
Lavado, E.A 115; A 84
Garcea, O.A 3; A 8; A 16; A 23; A 7
Elliff, D.A 83
Hauser, S.A 161; A 162
Lehr, L.A 129
García, F.A 122
Enríquez, F.A 80
Havrdova, E.A 24; A 59
Garcia, Y.A 150
Garrahan, J. P 12
Escobar, D.A 83
Léllis, B.A 141
Hernandez, F.A 91
León, A.A 23
Espinoza, S.A 119; A 120; A 121; A 63; A 122
Gasparetto, E. A 55; A 132; A 134; A 144; A 4;
A 54; A 12; P 19
Fajardo, C.A 19
Herrmann, J.A 44
Leon, R.A 127; A 146; A 82
Hobi, C.A 128
Leppert, D.A 161; A 162
Georgeto, S.A 137; A 138
Falcón-Cama, V.A 76
Horta, W.A 10; A 9
Levya, L.A 65
Gerber, M.A 162
Faria, T.A 124; A 101
Hotermans, C.A 59
Li, D.A 161
Ghezzi, A.A 129
Farias, A.A 154; A 165; A 52
Inojosa, J.A 83
Liguori, N.A 3; A 8; A 16; A 23; A 7
Giacomo, M.A 83
Farinhas, J.A 31; A 67
Islas, M.A 160; A 163; A 27; A 45;
A 80; A 110
Lima, A.A 109; A 57
Fazzito, M.A 128
Giunta, D.A 160
Fernandes, A.A 133
Itagiba,V.A 132; A 4
Lima, M.A 112
Fernandes, E.A 26; A 38
Glehn, F.A 165; A 52; A 71
Gold, R.A 24;A 46;A 59
Jiménez, G.A 122
Lin, K.A 83
Fernández, O.A 65; A 159; A 23; P 6
Gomes Neto, A.A 135;A 28;A 47;A 93;A 5
Jorge, F.A 128
Linhares, U.A 97; A 38
Fernández-Masso, J.A 76
Gomes, B.A 141
Ferreira, M.A 137;A 138;A 152
Gomes, M.A 17; A 18
Kaimen-Maciel, D.A 104; A 115; A 73; A 83;
A 84; A 148; A 35;A 137;
A 138
Longhini, A.A 154; A 52
Lopategui-Cabeza, I.A 81
Ferrer, O.A 116
Gomes, S.A 126; A 137; A 138; A 147;
A 51; A 83
Kallaur, A.A 104; A 115; A 73; A 84;
A 148; A 35
Lopes, F.A 39; A 132; A 134; A 144; A 4;
A 12; A 54; A 55
Fêzer, L.A 138; A 167; A 36; A 40; A 53;
A 58; A 96; A 55
Gómez, J.A 68; A 76; A 95; A 81; P 17
Kallembach, J.A 30; A 92
Lopes, J.A 104; A 115;A 137; A 138;
A 148; A 73; A 83;A 84; A 35
Figueiredo, A.A 9; A 10
Gomez, S. A 50
Kappos, L.A 161; A 162; A 90; A 44
Fink, M.A 101; A 124
Gómez-Añón, A.A 158
Kawagoe, K.A 115; A 84
Finkelsztejn, A. A 17;A 18
Gonçalves, M.A 123; A 137; A 138; A 51;
Kay, C.A 94
Lopes, K.A 32
López, E.A 80
López-Saura, P.A 81
50
51
Melcon, M. A 48; A 83; P 2
Lorenzoni, P.A 94
Lourenço, G.A 36; A 40; A 58; A 83
Melo, P.A 128
Meltzer, L.A 59
Luetic, G.A 90
Mendes, M.A 137; A 138
Luis S NaliA 124
Mendive, M.A 79
Nóbrega Junior, A.A 123
Peçanha Neto, S. P 18
Nóbrega, F.A 32
Pedroso-Santana, S.A 95
Nogales-Gaete, J.A 120; A 119; A 121; A 63;
A 122
Peixoto, E.A 38
Peixoto, M.A 128
Nogueira, L.A 111; A 139; A 151; A 66
Pelegrino, L.A 104; A 35; A 84
Merino, A.A 8
Lyrio, M.A 133; A 114
Nogueira, S.A 32
Machado, M. A 152
Penna e Costa, A.A 117; A 56; A 70
Merino, P.A 122; A 119; A 120; A 121;
A 63
Novas, M.A 24; A 59
Miguez, J.A 15; A 42
Novis, S.A 53; A 167
Miller, D.A 44; A 46
O-Connor, P.A 161
Miraldi, F.A 54
Oehninger, C. A 158
Moises, F.A 45; A 80
Oger, J.A 131
Molina, O.A 116; A 77; A 127; A 146;
A 82
Oliva, T.A 115
Pentón-Arias, E.A 76
Machado, S.A 123
Pentón-Rol, G.A 76; A 95; A 81
Machnicki, G.A 160; A 34; A 48
Peralta, S.A 79
MacManus, D. A 46
Pereira, A.A 49
Magalhães, E.A 117; A 56; A 70
Pereira, B.A 83
Malfetano, F.A 144; A 54; A 138; A 36; A
40;
A 58; A 9; A 96; A 10
Pereira, D.A 19
Olival, G.A 101; A 124; A 33; A 41
Oliveira, E.A 154; A 165
Pereira, F.A 49; A 74
Pereira, V.A 144; A 9; A 36; A 40; A 10;
A 58; A 88; A 96
Oliveira, F.A 126; A 138; A 83; A 137;
A 51; A 147
Pereira, W.A 115; A 84; A 104; A 73;
A 35; A 148
Oliveira, S.A 115; A 84; A 104; A 73; A
35;
A 148
Pérez, A.A 53
Pessôa, F.A 134; A 12
Peterlevitz, A.A 165
Moral, E.A 79
Oliveira,C.A 83; A 2; A 126; A 137; A
138;
A 51
Martins, C.A 144
Morales, N.A 83
Ordaz, E.A 50
Piccolo, A.A 153; A 20
Masterman, D.A 161
Morales, R.A 138; A 137; A 83
Ortiz, G.A 45; A 80
Pimentel, M.A 53; A 167
Matheus, N.A 26; A 38
Moreira, A. A 152
Otranto, K.A 53
Pinto, L.A 26
Matos, K.A 19
Moreira, M.A 83
Pace, A.A 59
Pinto, S.A 106
Matta, A.A 67
Moreira, S.A 83
Matta,A.A 31
Morimoto. H.A 148; A 73; A 35
Paes, R.A 109; A 57; A 29; A 107; A 30
Paiva, C.A 74; A 10; A 9
Pires, C.A 55
Pleimes, D.A 44
McIIroy, C.A 129
Muniz, A.A 137; A 138
Pamplona, R.A 79
Pohl, D.A 129
Medeiros, M.A 115; A 84
Nali, L.A 101; A 33
Panis, CA 104
Pohl,C.A 44
Meinel, M.A 129
Nascimento, O.A 67; A 31
Paradela, E.A 10; A 9
Polman, C.A 44
Meira, I.A 54; A 9; A 58; A 36; A 40;
A 10; A 96; A 138
Naylor, R.A 90
Paredes, M.A 118
Portero-Otin, M.A 79
Nazabal-Galvez, M.A 95; A 76
Patrucco, L.A 6; A 13; A 14; A 15; A 42;
A 61; A 78; A 11; P 10
Pradella, F.A 154; A 165; A 60; A 71
Mandler, R. Moll, F.A 166
P 14
Oliveira, A.A 101; A 33
Marcilla, M. A 48
Marin, K.A 26; A 38
Montalbán, X.A 44
Marinho, P.A 102; A 142
Monteiro, T.A 30; A 57
Martinez, A.A 83; A 75; A 143
Moraes, A.A 165; A 52; A 154
Martínez, A.A 43
Moraes, L.A 101; A 128; A 33
Martínez, F. A 158
Moraga, M.A 129
Martínez-Sánchez, G.A 81
Monteagudo, A.A 68
Meirelles, A.A 56
Phillips, J.A 24; A 59
Prado, F.A 31
Neri, V.A 140; A 89; A 38
Paula, R.A 154; A 165
Melamud, L.A 100; A 99
Quero, C.A 56; A 70
Netto, S.A 26
Pavón-Fuentes, N.A 95
52
53
Raghupathi, K.A 24
Russo, L.A 83
Selmaj, K.A 24; A 59
Torres, D.A 19
Sá, M.A 117
Serafim, V.A 101; A 124; A 41
Torres, Y.A 112
Sá, R.A 56
Shearer, K.A 83
Trigueros, J.A 108
Sabino, P.A 111; A 139; A 151; A 66
Silva, B.A 8; A 23; A 7; A 3; A 16
Tukada, D.A 52
Safanelli, F.A 137; A 138
Silva, C.A 126; A 51
Umaki, D.A 102; A 142
Safanelli, J.A 83
Silva, J.A 67
Valenzuela-Silva, C.A 81
Rametta, M.A 131
Ramirez, V.A 45
Ramos, J.A 80
Ravelo, M.A 127; A 146; A 82
Reder, A.A 131
Reich, E.A 125
Saladino, M.A 16
Silva, L.A 52
Vanotti, S.A 8; A 100; A 85; A 99
Reiche, E.A 115; A 84; A 104; A 73; A 35;
A 148
Sales, D.A 133; A 114
Silva, N.A 17; A 18
Resk, M. A 48
Salfate, C.A 122; A 119; A 121; A 63
Simão, A.A 104; A 148; A 73; A 35
Ribeiro, A.A 114
Salgado, P.A 137; A 138
Simm, R.A 101; A 33; A 128
Vasconcelos, C.A
A
A
A
A
Ribeiro, J.A 83
Sinnett, M.A 149; A 75; A 87
Vasquez, L.A 150
Ribeiro, S.A 126; A 51; A 83
Salles, R.A 117
Salles, T.A 56; A 70
Siqueira, H.A 141
Rios, G.A 91
Samira ApostolosA 128
Siquineli, F.A 126; A 51; A 83
Vazquez, T.A 160; A 157; A 150
Velador, E.A 80
Ritter, S.A 90
Sanchez, E.A 45
Soto, A.A 105; A 127; A 146; A 50;
A 64; A 82; A 116
Rivera, J.A 150; A 160
Sanchez, J.A 118
Sánchez, M.A 80
Soto, I.A 127; A 146; A 82; A 77; A 69
Rocha, M.A 153; A 20
Sandbrink, R.A 44
Souza, A.A 171
Souza, L.A 30
Rodrigues, B.A 38; A 103; A 66
Santana, D.A 70
Rocha, C.A 10; A 9
Rodrigues, D.A 57
Santiago, T.A 33
Rodrigues, M.A 2
Santos, C.A 38
140; A 37; A 86; A 32;
133; A 97; A 32; A 1; A 13;
38; A 89; A 30; A 57; A 92; 21; A 49; A 107; A 65;
74; P 11
Viglietta, V.A 24; A 46
Villa, A. A 48; A 100; P 5
Villalobos, V.A 116; A 77
Villarreal-Barrios, A. A 95
Viridiana, R.A 110; A 163; A 27
Souza, R.A 115; A 84; A 135; A 28; A
47;
A 5; A 93
Volpini, W.A 165
Vrech, C.A 43; A 143
Spagnol, G.A 154
Santos, G.A 140; A 37; A 136; A 21; A 92; A 30; A 1 ; A 65; A 57; A 38;
A 72
Rodríguez, C.A 83
Rojas, G. A
Rojas, J.A
A
A
143; A 75; A 43
Werneck, L.A 94
Steinberg, J.A 75; A 143; A 43
Wilner, N. A 55; A 39
Stemper, B.A 44
Yang, M.A 24
Santos, L.A 52; A 154; A 165
160; A 11; A 13; A 14; A 15;
34; A 42; A 6; A 61; A 78;
48
Stephan, M.A 46
Yousry, T.A 46
Santos, L.A 111; A 151; A 66
Sumita, L.A 33; A 101; A 124
Ysrraelit, C. A 48
Santos, M.A 154; A 165; A 71
Rojas, S.A 119; A 121; A 63; A 122
Sweetser, M.A 24
Zalcman, J.A 127; A 146; A 82
Santos, S.A 117
Romano, C.A 101; A 124; A 33
Romano, M.A 160; A 34
Takemoto, M.A 17; A 18
Zamalloa, C. A 22
Sarmento, E.A 49
Tenembaum, S.A 129; P 12
Zamorano, V.A 122; A 119; A 121; A 120;
A 63
Sassi, R.A 25
Roque, E.A 108
Thomaz, R.A 101; A 124; A 33; A 41
Rosa, A. A 45
Sato, D.A 128
Rosalino, J.A 147
Satomi, M.A 137; A 138
Ruiz, L.A 79
Sauter, A.A 161
Ruiz, M.A 149; A 62; A 75; A 87
Scola, R.A 94
Ruocco, H.A 126; A 137; A 51; A 138
Seifer, G.A 48
Zhang, R.A 46
Thuler, L.A 133; A 32; A 151; A 111;
A 136; A 66; A 30; A 92;
A 97
Zumaeta, S.A 119; A 121; A 63; A 122;
A 120
Tilbery, C.A 101; A 124; A 33; A 41
Tinbergen, J.A 161; A 162
Tomic, D.A 90
54
55
ORAL PRESENTATION
NOVEMBER 30th
NOVEMBER 29th
ABSTRACT
ID
A 62
A 95
TITLE
TIME OF
PRESENTATION
SESSION
Genetic variability in Peruvian
Idiophatic
patients with relapsing remitting
Inflammatory
multiple sclerosis, using STR
15:25 to 15:40
demyelinating
markers DYS390, DYS391,
Diseases (IIDD) in
DYS392 Y chromosome
Latin America
Neuromyelitis Optica and Multiple
Idiophatic Inflammatory
Sclerosis: A View from DNA, RNA
15:35 to 15:45
and Protein Profiles.
demyelinating Diseases
ROOM
treated with immunomodulator
A 74
familial cases in a reference center in the
at public healthy system in Chile,
demyelinating Diseases
A 81
Oriente
A 50
A 51
Ruiz
A 52
17:45 to 17:55
MS: Latin American
Epidemiology of Multiple Sclerosis
Neuroepidemiology in
17:55 to 18:05
MS: Latin American
Venezuela
Studies
Epstein-Barr virus and smoking
18:05 to 18:15
MS: Latin American
multiple sclerosis
Studies
Epstein-Barr vírus infection of
the central nervous system and
18:15 to 18:25
multiple sclerosis disease activity
A 124
A3
Oriente
Giselle Penton-Rol
A 41
multiple sclerosis: follow-up of 40
pathogenesis and response to therapy of
15:30 to 15:45
HOT TOPICS
Segóvia I
15:45 to 16:00
HOT TOPICS
Segóvia I
MS: Latin American
Oriente
Jorge Elías Nogales-Gaete
A 21
A 42
source for endogenous retrovirus and
its association with the multiple sclerosis
Acute Disseminated Encephalomyelitis:
Presentation in the adult population.
16:30 to 16:40
for the diagnosis of Multiple Sclerosis in
an argentinean cohort of patients with
16:40 to 16:50
Clinical Analysis of malignant MS in a
brazilian reference center for MS
16:50 to 17:00
Segóvia II
Nora Fernández Liguori
A 92
Segóvia II
Arnoldo Soto
17:00 to 17:10
Multiple Sclerosis: natural history and
prognostic factors in Brazilian patients.
17:10 to 17:20
Prevalence of pseudotumoral
A 112
demyelinating lesions in an oncology
17:20 to 17:30
reference center
Segóvia II
Fabio Siquineli
Brain Atrophy as a non response predictor
A 11
to interferon? In Relapsing Remitting
17:30 to 17:40
Multiple Sclerosis
Carlos Otávio Brandão
A 12
Llanos
Guilherme Sciascia
do Olival
LACTRIMS Oral
Presentation MS
Segóvia III
Ricardo Alonso
LACTRIMS Oral
Presentation MS
Segóvia III
Liiana Patrucco
LACTRIMS Oral
Presentation MS
LACTRIMS Oral
Presentation MS
LACTRIMS Oral
Presentation MS
LACTRIMS Oral
Presentation MS
LACTRIMS Oral
Presentation MS
Fabrício da Costa
Segóvia III
Hampshire de
Araújo
Segóvia III
Liliana Patrucco
Gutemberg
Segóvia III
Augusto Cruz dos
Santos
Segóvia III
Segóvia III
Yasmine Coura
Torres
Juan Ignacio Rojas
Segóvia I
Cavenaghi; Vitor Serafim;
Sclerosis patients: a comparison study
with Clinically Isolated Syndrome and
17:40 to 17:50
LACTRIMS Oral
Presentation MS
Segóvia III
Fernanda Miraldi
Clemente Pessôa
Cytokine profile in relapsing-remitting
A 35
multiple sclerosis patients and the
association with the progression and the
17:50 to 18:00
LACTRIMS Oral
Presentation MS
Segóvia III
Ana Paula Kallaur
activity of the disease
Rodrigo Barbosa Thomaz;
Resting-state functional Magnetic
A 54
Resonance Imaging in the assessment of
17:50 to 18:10
patients with neuromyelitis optica
56
Majel Cervantes-
Brain atrophy evaluation in Multiple
Segóvia II
Olival; Vitor Breseghello
patients.
Sscleosis in a cohort of argentinean
patients
Guilherme Sciascia do
HOT TOPICS
Alvarenga
clinically isolated syndromes
Studies
16:00 to 16:15
Marcos Papais
Aplication of the Mcdonald 2010 criteria
A6
Disease modifying therapy
withdrawal in relapsing-remitting
Segóvia I
etiology
Studies
habits in Brazilian patients with
HOT TOPICS
Prognostic factors of malignant multiple
with multiple sclerosis
in the island Oo Margarita,
15:15 to 15:30
FIRST AUTHOR
Research of locus Xq22.3 as transcription
Miguel Ernesto Cordova
(IIDD) in Latin America
Breastfeeding and risk of
postpartum relapses in women
ROOM
Demyelinating diseases
2008-2012
A 16
SESSION
Molecular targets involved in
Idiopathic Inflammatory
15:15 to 15:25
TIME OF
PRESENTATION
city of Rio de Janeiro.
FIRST AUTHOR
Geographical distribution of
A 63
TITLE
Inter- and intragenerational study of MS
(IIDD) in Latin America
patients with multiple sclerosis
ABSTRACT
ID
57
NMO
Segóvia II
Emerson Leandro
Gasparetto
E-Poster ANERJ presentation
ABSTRACTS
ID
TITLE
AUTHOR
DATE OF
PRESENTATION
TV
Camila
Rodrigues
de Almeida
NOVEMBER 28th
ANERJ 02
Depressão induzida por interferon:
homogeneidade de magnitude de
sintomas depressivos somáticos e
cognitivos em estudo prospectivo em
pacientes com hepatite C
Lucas Pereira
Jorge de
Medeiros
NOVEMBER 28th
ANERJ 03
Multiple Sclerosis Lesion Heart x
Mitoxantro
Francisco T.
M. Oliveira
NOVEMBER
28th
1
16:20 às 16:30
ANERJ 04
Neuromyelitis Optica X SPECTRUM
manifestation.
Franciso T.
M. Oliveira
NOVEMBER 28th
2
16:00 às 16:10
ANERJ 05
Injuries of neuroimaging neuritis optical
and neuromyelitis optica.
Francisco T.
M. Oliveira
NOVEMBER 28th
ANERJ 06
Terapia infusional com natalizumabe
em pacientes com esclerose: desafio
para o enfermeiro no brasil
Fabiana dos
S Carolino
Firmo Pereira
ANERJ 07
ANERJ 08
Programa de treinamento físico como
fator adjuvante no tratamento da
esclerose múltipla
A Forma Benigna da Esclerose Múltipla:
uma revisão sistemática
Regina
Alvarenga
Thais
Conceição
Monteiro
NOVEMBER 28th
NOVEMBER 28th
NOVEMBER 28th
1
1
2
2
3
3
Antonio
Carlos
Andrade
Alvarenga
Filho
NOVEMBER 28th
5
16:10 às 16:20
ANERJ 15
Neuro Behçet:Importância do
Diagnóstico Diferencial
Vanderson
Carvalho
Neri
NOVEMBER 28th
5
16:20 às 16:30
ANERJ 16
Arqueopatologia e dados históricos dos
defeitos de formação do Tubo Neural
Renato
Manganelli
Salomão
NOVEMBER 28th
6
16:00 às 16:10
ANERJ 17
Paralisia periodica Hipocalemica
Francisco
T.M.Oliveira
NOVEMBER 28th
6
16:10 às 16:20
ANERJ 18
Prevalência de Achados
Orofaringoscópicos em Pacientes
com Roncos Noturnos estudados no
Hospital Universitário Gaffrée e Guinle
Felipe de
Oliveira
Figueiredo
NOVEMBER 28th
6
16:20 às 16:30
ANERJ 19
Carcinomatose leptomeníngea: relato
de caso
Isabella
Cristina Silva
Defanti
NOVEMBER 28th
7
16:00 às 16:10
ANERJ 20
Paquimeningite em Granulomatose de
Wegener
Antonio
Pereira
Gomes Neto
NOVEMBER 28th
7
16:10 às 16:20
ANERJ 21
Primary vasculitis of the central nervous
system: a case report
Tatiane de
Souza Pinto
NOVEMBER 28th
7
16:20 às 16:30
ANERJ 22
Comparação esportômica do
metabolismo de amônia em atletas de
elite durante diferentes protocolos de
treinamento e análise de VO2max
André
Nascimento
Monteiro
NOVEMBER 28th
8
16:00 às 16:10
ANERJ 23
Metabolismo de aminoácidos e de
amônia no desenvolvimento da fadiga
central. Uma revisão da literatura atual.
Luis Eduardo
Viveiros de
Castro
NOVEMBER 28th
8
16:10 às 16:20
Elizabeth
Cataldi
NOVEMBER 28th
8
16:20 às 16:30
TIME OF
PRESENTANTION
Disfunção urinária em mulheres com
Esclerose múltipla do Rio de Janeiro
(Brasil)
ANERJ 01
ANERJ 14
Osteoporose em homem de 50 anos
com esclerose múltipla forma surtoremissão. Relato de caso.
16:00 às 16:10
16:10 às 16:20
16:10 às 16:20
16:20 às 16:30
16:00 às 16:10
16:10 às 16:20
Nível sérico de vitamina D em pacientes
com Esclerose Múltipla atendidos na
cidade do Rio de Janeiro
Soniza Vieira
Alves Leon
ANERJ 10
Espectro Neuromielitis Optica
Veronica
Fleitas
NOVEMBER 28th
4
16:00 às 16:10
ANERJ 24
ANERJ 11
Hemianopsia homônima como
Sindrome Clinica Isolada com alto
poder de conversão para Esclerose
Múltipla em paciente na quinta década
de vida. Relato de caso.
Concentrações plasmáticas de Alanina;
Glutamato; Glutamina e metabolismo
de amônia durante sessões repetidas
de luta em alta intensidade e curta
duração. Uma análise esportômica.
Eduardo
Cukierman
NOVEMBER 28th
4
16:10 às 16:20
ANERJ 25
O que a população (des)conhece sobre
epilepsia
Yara Dadalti
Fragoso
NOVEMBER 29th
1
16:00 às 16:10
ANERJ 26
O número de casos de Epilepsia de
Etiologia Estrutural/Metabólica pode
ser diminuído?
Juliane
Sauter
Dalbem
NOVEMBER 29th
1
16:10 às 16:20
ANERJ 27
Tradução, retrotradução e aplicação
do questionário de Limoges (França)
numa população de pacientes com
diagnóstico de epilepsia na cidade de
Eunápolis - Bahia
Pablo
Machado
Loureiro
NOVEMBER 29th
1
16:20 às 16:30
ANERJ 09
ANERJ 12
ANERJ 13
Principais efeitos colaterais do uso de
Interferon Beta 1a e Interferon Beta
1B subcutâneo nos pacientes com
Esclerose Múltipla da Santa Casa da
Misericórdia do Rio de Janeiro.
Wagner
Horta
Elaboração de um questionário para
identificar a presença de comorbidades
em uma série de pacientes com
Esclerose Múltipla na cidade do Rio de
Janeiro.
Maristela
Cavedagne
58
NOVEMBER
28th
NOVEMBER 28th
NOVEMBER 28th
3
4
5
16:20 às 16:30
16:20 às 16:30
16:00 às 16:10
59
ANERJ 28
Epilepsia Mioclônica Juvenil ? Relato
em gêmeas univitelínicas
Cláudia
Cecília da
Silva Rêgo
NOVEMBER 29th
2
16:00 às 16:10
ANERJ 29
Epilepsia mioclônica juvenil ?
paradigma entre focal e generalizada ?
Relato de caso.
Ana Carolina
Gomes
Baltar
NOVEMBER 29th
2
16:10 às 16:20
Epilepsia Mioclônica Juvenil: autopercepção de fatores precipitantes de
crises X registros ictais de ativações
investigados por vídeo-EEG
Cláudia
Cecília da
Silva Rêgo
NOVEMBER 29th
Mioclonias periorais vs Automatismos
orais ? Relato de Caso
Soniza Vieira
Alves Leon
NOVEMBER 29th
ANERJ 30
ANERJ 31
ANERJ 32
Percepção dos estudantes de medicina
acerca da epilepsia
JULIANE
SAUTER
DALBEM
NOVEMBER 29th
2
3
3
NOVEMBER 29th
3
16:20 às 16:30
ANERJ 34
Padrões Periódicos no
Eletroencefalograma: Revisão
Mariana
Silva Souza
NOVEMBER 29th
4
16:00 às 16:10
ANERJ 35
Padrão Eletroencefalográfico Periódico:
Aspectos Clínicos, Neuroimagem e
Evolução
Mariana
Silva Souza
ANERJ 36
Síndrome do Homem Rígido: relato de
caso
Clarissa N.
Spitz
NOVEMBER 29th
4
16:20 às 16:30
ANERJ 37
Estudo clínico, polissonografico e
do HLA Classe II em uma série de
pacientes brasileiros narcolépticos
Andrea
Bacelar
NOVEMBER 29th
5
16:00 às 16:10
38. Paraplegia Espástica Hereditária
(Síndrome de Staümpell Lorrain):
relato de quatro casos em uma mesma
família
Vanderson
Carvalho
Neri
NOVEMBER 29th
5
7
16:10 às 16:20
ANERJ 45
Qual é o sintoma mais precocemente
relacionado aos tumores malignos do
nervo periférico na neurofibromatose?
Roberto
Andre
Torres de
Vasconcelos
NOVEMBER 29th
7
16:20 às 16:30
ANERJ 46
Polirradiculoneuropatia associada
a quadro reacional em hanseníase:
Relato de caso
Louise Mara
Giesel
NOVEMBER 29th
8
16:00 às 16:10
ANERJ 47
Schwannoma do nervo facial ? Relato
de caso e revisão da literatura
Christiano
Assis
Buarque
Perlingeiro
NOVEMBER 29th
8
16:10 às 16:20
ANERJ 48
Prevalência e características de
dor lombar em uma população de
universitários jovens da área da saúde
do município de Santos.
Yara Dadalti
Fragoso
NOVEMBER 29th
8
16:20 às 16:30
ANERJ 49
Avaliação do tremor do palato
mole e laringe através da
fibronasofaringolaringoscopia em
pacientes com doença de Parkinson
Daniella
Leitão
Mendes
NOVEMBER 30th
1
16:00 às 16:10
ANERJ 50
Relação do tempo de doença,
distúrbios motores e quantidade de
cuidadores em pacientes com Doença
de Huntington ? estudo piloto
Rafael
Gonzalez de
Oliveira
NOVEMBER 30th
1
16:10 às 16:20
ANERJ 51
Mioclônus Palatal - Relato de caso
Carlos
Eduardo
Dilen da
Silva
NOVEMBER 30th
1
16:20 às 16:30
ANERJ 52
Estudo intergeracional da Doença
de Huntington: dificuldades de
aconselhamento genético preventivo
em pacientes com alelos de
penetrância reduzida
Luciana de
Andrade
Agostinho
NOVEMBER 30th
2
16:00 às 16:10
NOVEMBER 30th
2
16:10 às 16:20
16:10 às 16:20
Shaylla Vilas
Bôas Vianna
ANERJ 38
NOVEMBER 29th
16:00 às 16:10
Doença de Lafora - Relato de caso
4
Ana Caroline
Siquara de
Sousa
16:20 às 16:30
ANERJ 33
NOVEMBER 29th
ANERJ 44
Estudo Sistemático Anátomo-Cirúrgico
dos Ramos do Nervo Musculocutâneo
para o Músculo Bíceps Braquial: Bases
Anatômicas para a Técnica de Oberlin
16:10 às 16:20
16:10 às 16:20
ANERJ 39
Sindrome Pos-Polio
jose
h.f.rosalino
ANERJ 40
The response of the Cutaneous Silent
Period in a group of patients with
tunnel carpal syndrome.
Joseph
Bruno Bidin
Brooks
NOVEMBER 29th
6
16:00 às 16:10
ANERJ 53
Hiperfagia na Doença de Alzheimer
Marcela
Rodrigues
Moreira
Guimarães
ANERJ 41
The response of the Cutaneous Silent
Period in a group of patients with
diabetes and polineuropathy.
Joseph
Bruno Bidin
Brooks
NOVEMBER 29th
6
16:10 às 16:20
ANERJ 54
Deficiency of vitamin B12 and
relationship with Neuro-Image
Sidney
Gomes
NOVEMBER 30th
2
16:20 às 16:30
ANERJ 42
Síndrome do Homem Barril como
apresentação secundária a osteoartrose
cervical: um relato de caso
Lucas
Oliveira
Mourão
NOVEMBER 29th
6
16:20 às 16:30
ANERJ 55
Efeitos da Vitamina K1 na cognição e
memória de ratos SHR-sp
Victor Agati
Cavargere
NOVEMBER 30th
3
16:00 às 16:10
ANERJ 56
Rastreio de síndrome frontal pelo
frontal Assessment Battery (FAB)
Rafael Neder
NOVEMBER 30th
3
16:10 às 16:20
ANERJ 43
Mononeuropatia Multipla e Sindrome
Churg Strauss
JHF.Rosalino
60
NOVEMBER 29th
5
16:20 às 16:30
NOVEMBER
29th
7
16:00 às 16:10
61
ANERJ 57
Estudo comparativo entre o
comprometimento cognitivo na
Síndrome de Sjögren e Esclerose
Múltipla
Dóra-Neide
Rodrigues
ANERJ 58
Características da cefaleia crônica
recorrente em crianças entre cinco e
nove anos de idade
Felipe
Moreira
Gannoum
NOVEMBER 30th
4
16:00 às 16:10
ANERJ 59
Demographic and Clinical Profile
of Paediatric Patients with Multiple
Sclerosis: A Cohort Study
Mar
Mendibe
Bilbao
NOVEMBER 30th
4
16:10 às 16:20
ANERJ 60
Singular associação de lesão pseudo
tumoral cerebral recorrente em
paciente pediátrico com neuromielite
óptica anti-AQP4 negativo
Natalia
Matheus
Terrana de
Carvalho
ANERJ 61
Cefaleia Numular
Sidney
Gomes
NOVEMBER 30th
5
16:00 às 16:10
ANERJ 62
Revisão sistemática do uso de
metoclopramida endovenosa no
tratamento agudo da enxaqueca
Yara Dadalti
Fragoso
NOVEMBER 30th
5
16:10 às 16:20
ANERJ 63
Bases genéticas de uma caso raro
de X-ALD forma cerebral infantil em
menina
Patricia
Reche
NOVEMBER 30th
5
16:20 às 16:30
Amnesia Global Transitoria
Jose
Henrique
Fernandes
Rosalino
NOVEMBER 30th
6
16:00 às 16:10
Francisco
T.M.Oliveira
NOVEMBER 30th
ANERJ 64
NOVEMBER 30th
NOVEMBER 30th
3
4
16:20 às 16:30
16:20 às 16:30
ANERJ 65
Dissecçoes Arteriais Espontaneas
Bilateral
ANERJ 66
Suplementação de alfa tocoferol
no status neurológicos de ratos
espontaneamente hipertensos com
propensão ao acidente vascular
encefálico (SHRSP) submetidos a
inibição do óxido nítrico (L-name).
Marcela
Rodrigues
Moreira
Guimarães
NOVEMBER 30th
6
16:20 às 16:30
ANERJ 67
A Acupuntura como terapia
coadjuvante na recuperação de
seqüelas de acidente vascular cerebral
Marcos
Barros
Caldeira de
Andrada
NOVEMBER 30th
7
16:00 às 16:10
ANERJ 68
Distúrbio da coagulação na doença
cérebrovascular: relato de caso
Sérgio
Augusto P.
Novis
NOVEMBER 30th
ANERJ 69
Ação da Riboflavina na Lesão
Neurológica após Bloqueio da NOS
Camille
Feitoza
França
NOVEMBER 30th
7
16:20 às 16:30
ANERJ 70
Meningite Criptococcica e surdez
súbita reversível : Um relato de caso
Maria
Helena de
Araújo Melo
NOVEMBER 30th
8
16:00 às 16:10
62
6
ANERJ 71
Mielite Meningocócica
Tania Regina
Dias Saad
Salles
NOVEMBER 30th
8
16:10 às 16:20
ANERJ 72
Paralisia Facial Periférica e Anacusia
Como Manifestação Inicial de
Neurossífilis
Carlos
Eduardo
Dilen da
Silva
NOVEMBER 30th
8
16:20 às 16:30
ANERJ 73
Encefalite límbica: uma apresentação
atípica de neurossífilis
Juliana
Rezende
Dutra
NOVEMBER 30th
8
16:20 às 16:30
ANERJ 74
What do patients know about
pregnancy in multiple sclerosis?
Cristiane
Borges
Patroclo
NOVEMBER 30th
1
10:00 às 10:10
ANERJ 75
Síndrome de tronco cerebral e
encefalopatia como manifestações do
espectro NMO.
Erlane
Fernandes
NOVEMBER 30th
1
10:10 às 10:20
ANERJ 76
Surdez em pacientes com esclerose
múltipla: 3 relatos de caso
Hugo Fraga
Barbosa
Leite
NOVEMBER 30th
1
10:20 às 10:30
ANERJ 77
Teste de Identificação Olfativa em
Pacientes Submetidos a Lobectomia
Temporal para Tratamento de Epilepsia
Temporal Mesial Refratária
Fernando
Andreiuolo
Rodrigue
NOVEMBER 30th
2
10:00 às 10:10
ANERJ 78
Perda auditiva por exposição
continuada a Níveis de Pressão Sonora
Elevada (NPSE): A proteção auditiva
adequada como um fator excludente
do nexo laboral
Jorge
Barbosa
Leite
NOVEMBER 30th
2
10:10 às 10:20
ANERJ 79
Desenvolvimento e implementação
de um sistema de banco de dados
relacional para estudo da prevalência
de esclerose múltipla no estado do Rio
de Janeiro.
Carlos
Alberto
Alves
NOVEMBER 30th
2
10:20 às 10:30
16:10 às 16:20
The abstracts of the 79 papers presented as E-Posters in the
7
16:10 às 16:20
5th Congress of the ANERJ are published in the supplementt of
the Revista Brasileira de Neurologia.
63
E-POSTER LACTRIMS
PRESENTATION
SESSION
TV
ABSTRACT ID
TITLE
TIME OF PRESENTATION
ASSOCIATION STUDY IN MULTIPLE SCLEROSIS
A9
12:30-14:00
(MS): CIITA GENE POLYMORPHISM (RS4774*C)
IN CONJUNCTION WITH THE HLA-DRB1*15:01+
12:30 - 12:40
HAPLOTYPE INCREASES THE SUSCEPTIBILITY TO MS.
ASSOCIATION STUDY OF IL7R? (CD127) GENE
NOVEMBER 28 TH
GENETICS OF THE IIDD
A 10
POLYMORPHISM (T244I) AND HLA CLASS II WITH
SUSCEPTIBILITY TO MULTIPLE SCLEROSIS IN A
12:40 - 12:50
BRAZILIAN SAMPLE
GENETIC VARIABILITY IN PERUVIAN PATIENTS WITH
IIDD - ABSTRACTS OF GENETIC EPIDEMIOLOGY AND PHYSIOLOGY
SESSION
TV
ABSTRACT ID
A 50
12:30-14:00
TITLE
EPIDEMIOLOGY OF MULTIPLE SCLEROSIS IN THE
ISLAND OF MARGARITA, VENEZUELA
12:30 - 12:40
TV 03
OF IDIOPATHIC
INFLAMMATORY
A 68
IDIOPATHIC INFLAMMATORY DEMYELINATING
DISEASES OF THE CNS IN CUBA
DEMYELINATING
12:40 - 12:50
RELAPSING REMITTING MULTIPLE SCLEROSIS,
USING STR MARKERS DYS390, DYS391, DYS392 Y
12:50 - 13:00
CHROMOSOME
Committee: Tereza
HIGH FREQUENCY OF HLA ALLELE DRB1*0301
Corona, Oscar Fernandez
EPIDEMIOLOGY
A 62
A 65
AMONG BRAZILIAN NMO PATIENTS FROM RIO DE
e Doralina Brum
JANEIRO (BRAZIL)
Secretary: André
TUMOR NECROSIS FACTOR BETA (TNF-?) NCOI
Figueiredo
A 148
GENETIC POLYMORPHISM IS ASSOCIATED WITH
MULTIPLE SCLEROSIS INDEPENDENTLY OF HLA-
13:00 - 13:10
13:10 - 13:20
DRB1*
DISEASES
MONTH OF BIRTH DOES NOT SEEM TO INTERFERE
TV 01
Committee: C. keitzoan,
A 83
Walter Rocca, M.
WITH THE PREVALENCE OF MULTIPLE SCLEROSIS
FOR SOUTH AMERICAN PATIENTS AT LATITUDES
A 95
NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS:
A VIEW FROM DNA, RNA AND PROTEIN PROFILES.
13:20 - 13:30
12:50 - 13:00
ZERO TO 40 DEGREES
Melcom, Antonio
A 88
Pereira Gomes Netto
A 131
Secretary: Heloíse
Siqueira
A 160
MULTIPLE SCLEROSIS IN THE CITY OF RIO DE JANEIRO
SURVIVAL OUTCOMES AND CAUSE OF DEATH FROM
THE 21-YEAR LONG-TERM FOLLOW-UP STUDY
SYSTEMATIC REVIEW OF MULTIPLE SCLEROSIS IN
LATIN AMERICA
13:00 - 13:10
13:10 - 13:20
SESSION
TV
ABSTRACT ID
TITLE
EARLY CLINICAL PREDICTORS OF SUSTAINED
DISEASE-ACTIVITY-FREE STATUS IN PATIENTS WITH
13:20 - 13:30
A 43
12:30-14:00
RELAPSING-REMITTING MULTIPLE SCLEROSIS
12:30 - 12:40
TREATED WITH INTERFERON BETA AND GLATIRAMER
SESSION
TV
ABSTRACT ID
TITLE
ACETATE
EARLY INITIATION OF INTERFERON BETA-1B AFTER
REACTIVATION OF DISEASE ACTIVITY IN PATIENTS
A 116
12:30-14:00
WITH MULTIPLE SCLEROSIS AFTER NATALIZUMAB
12:30 - 12:40
DISCONTINUATION: A CASE REPORT IN VENEZUELA.
A FIRST CLINICAL EVENT SUGGESTIVE OF MULTIPLE
TREATMENT
A 44
A 76
MOLECULAR MECHANISMS ASSOCIATED TO A NEW
EXTENSION STUDY
12:40 - 12:50
COMBINED THERAPY FOR MULTIPLE SCLEROSIS
EFFECT OF FISH OIL ON CYTOKINES, OXIDATIVE
MONITORING ALGORITHM FOR PATIENTS WITH
A 82
MULTIPLE SCLEROSIS THAT INITIATE THERAPY WITH
TV 04
A 45
Carrá, Juan Bonito
TV 02
12:50 - 13:00
Committee: Edgardo
INTERFERON BETA-1A IN TREATMENT OF
RELAPSING-REMITTING MULTIPLE SCLEROSIS:
Cristiano, Rodrigo
13:00 - 13:10
SUBGROUP ANALYSIS OF THE LATIN-AMERICAN
Secretary: Fabricio da
COHORT IN TRANSFORMS STUDY
Armas Secretary: Ana
NEW PREDICTIVE MARKERS FOR NATALIZUMAB-
Beatriz Pereira
A 101
ASSOCIATED PROGRESSIVE MULTIFOCAL
13:10 - 13:20
ON MAGNETIC RESONANCE IMAGING (MRI)
A 46
THE PROFILE OF NATALIZUMAB ADVERSE EVENTS IN
PATIENTS WITH MULTIPLE SCLEROSIS
64
13:00 - 13:10
THE PHASE 3 DEFINE AND CONFIRM STUDIES
GASTROINTESTINAL TOLERABILITY EVENTS IN
A 59
LEUKOENCEPHALOPATY, PRELIMINARY RESULTS.
A 138
OUTCOMES IN RELAPSING?REMITTING MULTIPLE
SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF
Thomaz e Elizabeth
e Charles Tilbery
Costa Araújo
12:50 - 13:00
EFFECTS OF ORAL BG-12 (DIMETHYL FUMARATE)
COMPARISON OF ORAL FINGOLIMOD WITH
A 90
STRESS MARKERS AND PROGRESSION DISABILITY IN
MULTIPLE SCLEROSIS
IMMUNOMODULATORS.
Committee: Adriana
12:40 - 12:50
DISEASE-MODIFYING THERAPY FROM THE BENEFIT
INTERFERON BETA AND C-PHYCOCYANIN:
TREATMENT
SCLEROSIS: CLINICAL OUTCOMES AND USE OF
RELAPSING?REMITTING MULTIPLE SCLEROSIS (RRMS)
PATIENTS TREATED WITH ORAL BG-12 (DIMETHYL
13:10 - 13:20
FUMARATE) IN DEFINE AND CONFIRM
13:20 - 13:30
A 147
TREATMENT OF DISEASE DEVIC WITH
PLASMAPHERESIS AND CORTICOID
65
13:20 - 13:30
SESSION
TV
12:00-14:00
ABSTRACT ID
A 51
ENVIRONMENTAL/
A 16
GENETIC RISK FACTOR
TITLE
EPSTEIN-BARR VIRUS AND SMOKING HABITS IN
BRAZILIAN PATIENTS WITH MULTIPLE SCLEROSIS
BREASTFEEDING AND RISK OF POSTPARTUM
RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS
12:00 - 12:10
SESSION
TV
ABSTRACT ID
TITLE
BURDEN OF MULTIPLE SCLEROSIS AND
12:30-14:00
A 18
UNMET NEEDS IN BRAZIL: WORK STATUS AND
12:10 - 12:20
RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS.) IN CHILE. DESCRIPTION OF SOCIOECONOMIC
A 52
NERVOUS SYSTEM AND MULTIPLE SCLEROSIS
DRUGS AND ECONOMY
A 121
12:20 - 12:30
ASPECTS AND IMPACT OF THE COST OF DRUG
A 36
ANALYSIS ON NEONATAL NEWBORN RESULTS
AMONG PACIENTS WITH MULTIPLE SCLEROSIS
(CABL).
BURDEN OF MULTIPLE SCLEROSIS AND UNMET
12:30 - 12:40
TV 07
A 17
NEEDS IN BRAZIL: PATIENT PREFERENCES FOR MS
MULTIPLE SCLEROSIS PATIENTS IN CLINICAL
REMISSION: ASSOCIATION WITH EXPANDED
12:40 - 12:50
A 40
Andrés Villa, Lucia
Vianna, Elizabeth Frota
AMONG MULTIPLE SCLEROSIS PATIENTS
COSTS OF MULTIPLE SCLEROSIS IN LATIN AMERICA
A 34
AND THE CARIBBEAN: SYSTEMATIC REVIEW OF THE
12:50 - 13:00
DEMOGRAPHIC AND CLINIC CHARACTERISTICS
Secretary: Mauricio
A 37
Borges
OF PATIENTS TREATED WITH NATALIZUMAB ? A
A 124
Yasmin Coura Torres
SOURCE FOR ENDOGENOUS RETROVIRUS AND
ITS ASSOCIATION WITH THE MULTIPLE SCLEROSIS
DISEASE MODIFYING THERAPY WITHDRAWAL
13:00 - 13:10
A 41
IN RELAPSING-REMITTING MULTIPLE SCLEROSIS:
SERUM LEVELS OF VITAMIN D IN BRAZILIAN
13:20 - 13:30
FOLLOW-UP OF 40 PATIENTS.
ETIOLOGY
A 126
13:10 - 13:20
BRAZILIAN PRELIMINARY STUDY.
RESEARCH OF LOCUS XQ22.3 AS TRANSCRIPTION
Secretary : Denise Costa,
13:00 - 13:10
LITERATURE
Cordoba e Cezar Caparo
TV 05
DETERMINING FACTORS IN DELIVERY ROUTE
Committee: Oscar
Gamarra, Miguel
DISABILITY STATUS SCALE
12:50 - 13:00
TREATMENTS
OXIDATIVE STRESS IN RELAPSING-REMITTING
A 104
12:40 - 12:50
THERAPY IN COMPLEX PATIENTS BARROS LUCO
DISEASE ACTIVITY
Baranzini, Carmen Paiva,
12:30 - 12:40
PRODUCTIVITY LOSS.
EPSTEIN-BARR VÍRUS INFECTION OF THE CENTRAL
Committee: Sérgio
13:10 - 13:20
VITAMIN D3-INDUCED IDO+ TOLEROGENIC
A 154
DCS REDUCES THE SEVERITY OF EXPERIMENTAL
13:20 - 13:30
SESSION
TV
ABSTRACT ID
AUTOIMMUNE ENCEPHALOMYELITIS
A 137
THE PROFILE OF JCV IN BRAZILIAN PATIENTS WITH
MULTIPLE SCLEROSIS USING NATALIZUMAB
12:30-14:00
A 48
12:30-14:00
A3
IIDD - FEATURES IN AL
Committee: Fernando
Bedoy, Jorge Nogales
e Vladimiro Sinay
Secretary: Renato
Salomão
ABSTRACT ID
A 112
TV 06
A 77
A 105
TITLE
ACUTE DISSEMINATED ENCEPHALOMYELITIS:
PRESENTATION IN THE ADULT POPULATION.
PREVALENCE OF PSEUDOTUMORAL DEMYELINATING
LESIONS IN AN ONCOLOGY REFERENCE CENTER
UNUSUAL PRESENTATION OF ACUTE HEMORRHAGIC
LEUKOENCEPHALITIS: A CASE REPORT
PARKINSONISM SECONDARY TO PROGRESSIVE
MULTIPLE SCLEROSIS
A 130
A 147
FATIGUE AND DISABILITY
TREATMENT OF DISEASE DEVIC WITH
PLASMAPHERESIS AND CORTICOID
66
UNMET NEEDS IN
12:30 - 12:40
GEOGRAPHICAL DISTRIBUTION OF PATIENTS
A 63
ECONOMY
TV
ENCOMS: TREATMENT EXPERIENCE, BURDEN, AND
13:30 - 13:40
TREATMENT, DRUGS AND
SESSION
TITLE
WITH MULTIPLE SCLEROSIS TREATED WITH
IMMUNOMODULATOR AT PUBLIC HEALTHY SYSTEM
IN CHILE, 2008-2012
TREATMENT EXPERIENCE, BURDEN, AND UNMET
12:30 - 12:40
A 145
Committee: Carlos
A 110
A SAMPLE OF MEXICAN PATIENTS WITH MULTIPLE
Cuevas, Raul Arcega
Secretary: Camille França
12:50 - 13:00
POSITIVE PREDICTORS OF DRUG ADHERENCE IN
13:00 - 13:10
SCLEROSIS
e Yara Fragoso
13:00 - 13:10
NEEDS (ENCOMS) IN MULTIPLE SCLEROSIS STUDY:
THE COSTS OF MS PATIENTS IN ARGENTINA
TV 08
12:40 - 12:50
12:50 - 13:00
12:40 - 12:50
FREQUENCY OF POSITIVITY IN JCV TESTING IN A
A 58
MS COHORT OF PATIENTS AND FOLLOW UP AFTER
13:10 - 13:20
NATALIZUMAB TREATMENT
13:10 - 13:20
13:20 - 13:30
DISEASE MODIFYING THERAPY WITHDRAWAL
A 41
IN RELAPSING-REMITTING MULTIPLE SCLEROSIS:
FOLLOW-UP OF 40 PATIENTS.
67
13:20 - 13:30
NOVEMBER 29 TH
SESSION
TV
ABSTRACT ID
TITLE
A 136
REMITTING MS: PROGNOSIS FACTORS IN BRAZILIAN
A 21
MS
CLINICAL ANALYSIS OF MALIGNANT MS IN A
BRAZILIAN REFERENCE CENTER FOR MS
12:30 - 12:40
Committee: Marcelo
MULTIPLE SCLEROSIS CENTRES IN SPAIN AND
12:40 - 12:50
A 25
Kremenchutzky,
CLINICAL FEATURES AND MULTIPLE SCLEROSIS
EPIDEMIOLOGICAL IN RIO GRANDE-RS.
12:50 - 13:00
A8
Committee:
A 27
Fernanda Mendes
A 28
A 29
Secretary: Simone Batista
A 86
A 42
Secretary: Juliana Calvet
PROGNOSTIC FACTORS OF MALIGNANT MULTIPLE
SCLEOSIS IN A COHORT OF ARGENTINEAN PATIENTS
FAMILIAL CASES IN A REFERENCE CENTER IN THE
AND COGNITIVE PERFORMANCE IN RELAPSING-
12:50 - 13:00
COGNITION AND PERSONALITY IN A SAMPLE OF
MEXICAN PATIENTS WITH MS.
COGNITION IN MULTIPLE SCLEROSIS
COGNITION IN THE INITIAL STAGE OF MULTIPLE
SCLEROSIS ? A PRELIMINARY STUDY
FATIGUE AND MAXIMAL EXERCISE CAPACITY IN
RRMS PATIENTS WITHOUT MOTOR DYSFUNCTION.
13:00 - 13:10
13:10 - 13:20
13:20 - 13:30
13:30 - 13:40
13:10 - 13:20
SESSION
INTER- AND INTRAGENERATIONAL STUDY OF MS
A 74
12:40 - 12:50
REMITTING MULTIPLE SCLEROSIS IN BUENOS AIRES
e Damácio Ramon
13:00 - 13:10
PERFORMANCE IN EARLY ONSET RELAPSING
ASSOCIATION BETWEEN CLINICAL PARAMETERS
Marco Moreira e
Claudia Vasconcelos
12:30 - 12:40
REMITTING MULTIPLE SCLEROSIS PATIENTS
Miguel Macias,
ARGENTINA
TV 01
IN BENIGN MULTIPLE SCLEROSIS: PRELIMINARY
A 78
AND MS
TV 03
CLINICAL COMPARATIVE STUDY BETWEEN TWO
A 23
A 30
JUXTACORTICAL LESION VOLUME AND COGNITIVE
FATIGUE, COGNITION
POPULATION
NATURAL HISTORY OF
TITLE
RESULTS.
THE LONG TERM CLINICAL COURSE OF RELAPSING-
12:30-14:00
ABSTRACT ID
COGNITIVE IMPAIRMENT AND MRI FEATURES
12:30-14:00
ABSTRACTS ON MS, CLINIC, INVESTIGATION, RADIOLOGY AND TREATMENT
SESSION
TV
TV
ABSTRACT ID
TITLE
A2
DIAGNOSIS AND PROGRESSION OF DISEASE
13:20 - 13:30
CITY OF RIO DE JANEIRO.
A ROLE FOR THE BLINK REFLEX TEST IN THE
12:30-14:00
12:30 - 12:40
ASSESSMENT IN MULTIPLE SCLEROSIS.
SESSION
TV
12:30-14:00
ABSTRACT ID
A 86
NATURAL HISTORY OF
A 87
MS
A 92
Committee: Liliane
TV 02
A 118
Patrucco, Andrés Villa
e Fabíola Malfetano
Secretary: Sandra Garcia
TITLE
MULTIPLE SCLEROSIS IN PATIENTS OF ETHNIC
SHIPIBO CONIBO IN PERU
MULTIPLE SCLEROSIS: NATURAL HISTORY AND
PROGNOSTIC FACTORS IN BRAZILIAN PATIENTS.
UNIT REGISTRATION DEMYELINATING DISEASES
12:30 - 12:40
A 119
PATIENTS TREATED WITH IMMUNOMODULATORS, IN
A 127
VENEZUELAN PATIENTS
68
A 111
WALKING
A 155
12:40 - 12:50
PREDICTIVE FACTORS FOR LOWER WALKING SPEED
IN PERSONS WITH MULTIPLE SCLEROSIS
12:40 - 12:50
TV 04
Committee: Fernando
13:00 - 13:10
Cárceres, Miguel Macias
e Alfredo Damasceno
Secretary: Andrea Bacelar
13:10 - 13:20
A 107
A 109
12:50 - 13:00
PERFORMANCE OF PATIENTS WITH MULTIPLE
SCLEROSIS IN D2 TEST
PERSONALITY AND MULTIPLE SCLEROSIS - A
PRELIMINARY STUDY
13:00 - 13:10
13:10 - 13:20
RELAPSING REMITTING MULTIPLE SCLEROSIS (RR-MS)
A 120
IN CHILE. THE SIX-MINUTE WALKING TEST IN THE
13:20 - 13:30
COMPLEX CARE PATIENTS BARROS LUCO (CABL)
A 125
13:20 - 13:30
1-MINUTE INTERVALS OF 6-MINUTES WALK TEST IN
MULTIPLE SCLEROSIS PATIENTS
12:50 - 13:00
THE PUBLIC SYSTEM, 2008-2012.
CLINICALLY ISOLATED SYNDROME: STUDY IN
PSYCHOLOGY AND
WALKING DISTANCES COMPARISON BETWEEN
RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) IN CHILE. CLINICAL CHARACTERIZATION OF
COGNITION,
A 151
SELF AWARENESS AND ANOSOGNOSIA IN MULTIPLE SCLEROSIS.
VALIDITY AND RELIABILITY OF BRAZILIAN VERSION OF THE
MULTIPLE SCLEROSIS WALKING SCALE (MSWS-12)
69
13:30 - 13:40
13:40 - 13:50
SESSION
TV
12:30-14:00
ABSTRACT ID
A 103
TITLE
OPTIC NEURITIS FREQUENCY IN PATIENTS WITH
MULTIPLE SCLEROSIS
12:30 - 12:40
SESSION
TV
ABSTRACT ID
A6
FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS IN
AN ARGENTINEAN COHORT OF PATIENTS WITH
A 156
12:30-14:00
TV 05
Committee: Luis Melges,
12:40 - 12:50
PEDIATRIC IIDD
A 91
CLINICALLY ISOLATED SYNDROMES GROUP IN BUENOS AIRES
A 126
12:50 - 13:00
CLINICAL AND RADIOLOGICAL CHARACTERISTICS
A 22
OF PATIENTS WITH MS IN THE NATIONAL POLICE
13:00 - 13:10
HOSPITAL 2000-2010, LIMA – PERU
Isabella D'Andrea Meira
e Carlos Oheringer
A 108
Secretary: Wagner Horta
A 64
A 86
SESSION
APPLICATION OF 2010 CRITERIA MCDONALD IN A
TV
PERIMETRIC AND FUNDOSCOPIC FINDINGS IN PATIENTS
WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON
HEMIFACIAL SPASM AS THE FIRST CLINICAL
MANIFESTATION OF MULTIPLE SCLEROSIS
ABSTRACT ID
TITLE
A 129
Committee: Silvia
13:10 - 13:20
RELAPSING/REMITTING, PRIMARY PROGRESSIVE AND
PAEDIATRIC PATIENTS WITH MULTIPLE SCLEROSIS:
REGIONAL OUTCOMES IN AN INTERNATIONAL
A 117
SUPRATENTORIAL LESION IN CHILDHOOD:
12:50 - 13:00
13:00 - 13:10
13:10 - 13:20
13:20 - 13:30
NEUROMYELITIS OPTICA (NMO)?
A 86
SESSION
TV
ABSTRACT ID
TITLE
A 72
SCLEROSIS:EXPERIMENT REALIZED AT THE LAGOA
13:30 - 13:40
INFUSION OF NATALIZUMAB IN MULTIPLE
12:30-14:00
12:30 - 12:40
HOSPITAL IN RIO DE JANEIRO
12:30 - 12:40
INTERFERON BETA AND C-PHYCOCYANIN:
TREATMENT
A 76
COGNITION, PAIN,
MOLECULAR MECHANISMS ASSOCIATED TO A NEW
12:40 - 12:50
COMBINED THERAPY FOR MULTIPLE SCLEROSIS
FATIGUE, DYSPHAGIA
A 66
COGNITIVE INFLUENCE ON WALKING OF MULTIPLE SCLEROSIS
PATIENTS IN THE ABSENCE OF CLINICAL DISABILITY
MONITORING ALGORITHM FOR PATIENTS WITH
12:40 - 12:50
A 82
AND SLEEP
A 67
PRELIMINARY RESULTS FROM A STUDY IN A
A 84
SCLEROSIS PATIENTS
13:00 - 13:10
MULTICENTER STUDY TO ASSESS COGNITIVE AND
TV 06
A 85
NEUROPSYCHIATRIC DISORDERS IN MULTIPLE
SCLEROSIS PATIENTS FROM LATIN AMERICA
Committee: Ana Lucia
INTERFERON BETA-1A IN TREATMENT OF
A 90
Brito, Valéria Coelho e
Luiz Eduardo Castro
A 115
Secretary: Helcio
SLEEP QUALITY AND DISEASE PROGRESSION
AMONG MULTIPLE SCLEROSIS PATIENTS
NEW PREDICTIVE MARKERS FOR NATALIZUMABA 101
IGG ANTIBODY POSITIVITY IN A REHABILITATION
ASSOCIATED PROGRESSIVE MULTIFOCAL
LEUKOENCEPHALOPATY, PRELIMINARY RESULTS.
13:20 - 13:30
A 117
SYMPTOMS OF OROPHARYNGEAL DYSPHAGIA IN
MULTIPLE SCLEROSIS: PREVALENCE AND CLINICAL
13:40 - 13:50
FINDINGS IN A BRAZILIAN POPULATION
RELAPSING REMITTING MULTIPLES SCLEROSIS (RRA 122
MS) IN CHILE. EVOLUTION OF DYSPHAGIA AND
13:50 - 14:00
DYSARTHRIA IN 84 PATIENTS
70
13:20 - 13:30
NEUROMYELITIS OPTICA (NMO)?
A 86
13:30 - 13:40
SUPRATENTORIAL LESION IN CHILDHOOD:
HOSPITAL IN BRASILIA - BRASIL
A 133
13:10 - 13:20
RECURRENT MYELITIS AND TUMEFACTIVE
NMO AND NMO COMPLEX: FREQUENCY OF NMOA 102
13:00 - 13:10
COHORT IN TRANSFORMS STUDY
Tharso Adoni Secretary:
13:10 - 13:20
RELAPSING-REMITTING MULTIPLE SCLEROSIS:
SUBGROUP ANALYSIS OF THE LATIN-AMERICAN
-RELACCEM STUDY: LONGITUDINAL ANALYSIS
Paes, Guillermo Gomez
12:50 - 13:00
COMPARISON OF ORAL FINGOLIMOD WITH
TV 08
12:50 - 13:00
TERTIARY CENTER
MOOD DISORDERS AND FATIGUE AMONG MULTIPLE
MULTIPLE SCLEROSIS THAT INITIATE THERAPY WITH
IMMUNOMODULATORS.
IDENTIFYING PAIN IN MULTIPLE SCLEROSIS:
Alvarenga Filho
12:40 - 12:50
RECURRENT MYELITIS AND TUMEFACTIVE
Secretary: Simone Cotrim
13:30 - 13:40
SCREENING BATTERY
e Jorge Nogales
SERUM LEVELS OF VITAMIN D IN BRAZILIAN
PEDIATRIC CASE OF MULTIPLE SCLEROSIS
BENIGN, USING A BRIEF NEUROPSYCHOLOGICAL
Committee: Renata
DEMYELINATING DISEASE IN PEDIATRICS.
A 53
13:20 - 13:30
MULTIPLE SCLEROSIS: A REALITY AS
RETROSPECTIVE STUDY (REPLAY)
Tenembaum, Tania
Saad e Gustavo Valle
CLINICAL COURSES OF MULTIPLE SCLEROSIS:
A 57
12:30 - 12:40
SUBCUTANEOUS INTERFERON BETA-1A IN
TV 07
FREQUENCY OF COGNITIVE CHANGES IN THREE
12:30-14:00
CHARACTERIZATION OF 100 PATIENTS WITH
MULTIPLE SCLEROSIS OF GOIAS
CLINICALLY ISOLATED SYNDROMES
A7
EPIDEMIOLOGICAL AND CLINICAL
APLICATION OF THE MCDONALD 2010 CRITERIA
IIDD: FEATURES IN AL
TITLE
71
13:30 - 13:40
NOVEMBER 30 TH
SESSION
TV
ABSTRACT ID
TITLE
12:30-14:00
A1
INVOLVEMENT IN A COHORT OF NMO BRAZILIAN
A 60
IIDD IMUNOLOGY
A 81
BIOMARKERS
12:30 - 12:40
A 70
PATIENTS FROM RIO DE JANEIRO
NATURAL HISTORY OF
A 26
NMO
Committee: Maria
TV 01
NEURITIS IN PATIENTS FROM RIO DE JANEIRO.
PREVALENCE OF THYROID DYSFUNCTION AND
AUTOIMMUNITY IN PATIENTS WITH NMO
A 96
Atoni e Ibis Soto
MULTIPLE SCLEROSIS PATIENTS AND OTHER CENTRAL
A 47
Alves
A 94
TV
ENCEPHALOPATHY IN NEUROMYELITIS OPTICA
NEUROMYELITIS OPTICA AFTER THYMECTOMY IN A YOUNG
MYASTHENIA GRAVIS PATIENT USING CYCLOSPORINE
Committee: Jorge
12:50 - 13:00
13:00 - 13:10
A 79
13:20 - 13:30
12:30-14:00
A 13
BRAIN ATROPHY IN RADIOLOGICALLY ISOLATED SYNDROMES
12:40 - 12:50
TREATMENT OF MS AND
TV
NMO
BRAIN ATROPHY OVER 1 YEAR OF DISEASE ONSET
PREDICTS LONG TERM CLINICAL STATUS IN RELAPSING
TV 02
A 15
Committee: José
Cabrera, Fernanda Moll
A 61
e Juan Pablo Princich
Secretary: Nádia Araújo
RADIOLOGICALLY ISOLATED SYNDROMES
GENDER RELATED DIFFERENCES IN ATROPHY AND LESION LOAD
IN MULTIPLE SCLEROSIS PATIENTS IN BUENOS AIRES, ARGENTINA
CORRELATION WITH DISABILITY PROGRESSION (EDSS)
IN RELAPSING?REMITTING (RRMS) AND SECONDARY
13:10 - 13:20
DEMYELINATION IS NOT ALWAYS MULTIPLE SCLEROSIS
72
Committee: Adriana
OF MULTIPLE SCLEROSIS DURING CHILDHOOD
12:50 - 13:00
13:20 - 13:30
13:30 - 13:40
THE SEVERITY OF EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS. THE ROLE OF PLASMACYTOID
13:00 - 13:10
INSULIN RESISTANCE IS ASSOCIATED WITH DISABILITY IN
MULTIPLE SCLEROSIS PATIENTS
13:10 - 13:20
PROTEIN LIPOXIDATIVE DAMAGE AS A POTENTIAL
13:20 - 13:30
13:30 - 13:40
ABSTRACT ID
TITLE
A 11
BRAIN ATROPHY AS A NON RESPONSE PREDICTOR TO
INTERFERON ? IN RELAPSING REMITTING MULTIPLE
SCLEROSIS
12:30 - 12:40
A 150
USE OF RITUXIMAB IN DEVIC´S DISEASE, TWO YEARS
FOLLOW UP. MEXICAN EXPERIENCE.
12:40 - 12:50
A 24
CLINICAL EFFICACY AND SAFETY OF ORAL BG-12
(DIMETHYL FUMARATE) IN RELAPSING?REMITTING
MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS
OF THE PHASE 3 DEFINE AND CONFIRM STUDIES
12:50 - 13:00
A 83
MONTH OF BIRTH DOES NOT SEEM TO INTERFERE WITH
THE PREVALENCE OF MULTIPLE SCLEROSIS FOR SOUTH
AMERICAN PATIENTS AT LATITUDES ZERO TO 40 DEGREES
13:00 - 13:10
A 89
CEREBROSPINAL FLUID FINDINGS IN A SERIES OF CASES OF
NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS: PRIMARY
PROGRESSIVE AND RELAPSING REMITTING FORMS.
13:10 - 13:20
A 79
LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS REVEALS
PROTEIN LIPOXIDATIVE DAMAGE AS A POTENTIAL
PATHOGENIC MECHANISM.
13:20 - 13:30
A 39
13:30 - 13:40
TV 04
Carrá, Suzana Machado
e Patricio Abad
PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
A 39
IMMUNOLOGIC MARKERS VS. THERAPEUTIC HANDLING
12:40 - 12:50
13:00 - 13:10
VISUAL EVOKED POTENTIALS MEASURE AND
A 153
RESPONSE TO THERAPY OF DEMYELINATING DISEASES
A 39
12:50 - 13:00
REMITING MULTIPLE SCLEROSIS
BRAIN VOLUME CHANGES MAY PREDICT CONVERSION IN
MOLECULAR TARGETS INVOLVED IN PATHOGENESIS AND
PATHOGENIC MECHANISM.
12:30 - 12:40
A 14
12:30 - 12:40
LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS REVEALS
13:10 - 13:20
A4
RADIOLOGY IN MS
A 73
Linhares
ADVANCED MRI TECHNIQUES FOR THE EVALUATION OF
DEMYELINATING DISEASES: WHAT IS FOR RESEARCH AND
WHAT IS FOR CLINICAL PRACTICE
12:30-14:00
MODIFIES THE PROINFLAMMATORY RESPONSE IN
DENDRITIC CELLS AND B LYMPHOCYTES
Secretary: Ulisses
SESSION
TITLE
A 71
e Elizabeth Frota
ABSTRACT ID
TV 03
Correale, Soniza Leon
NERVOUS SYSTEM DEMYELINATING DISEASES
Secretary: Carlos Alberto
IN VIVO ADMINISTRATION OF TLR AGONIST REDUCES
12:40 - 12:50
NEUROMYELITIS OPTICA FREQUENCY IN A COHORT OF
Lucia Pimentel, Tarso
SESSION
A 113
CLINICAL PROFILE OR RECURRENT /BILATERAL OPTIC
TITLE
EXPERIMENTAL AUTOIMMUNE NEURITIS
A LONGITUDINAL STUDY OF BRAINSTEM
12:30-14:00
ABSTRACT ID
G-CSF ENHANCES FOXP3+ T LYMPHOCYTES AND
ABSTRACTS ON NMO, CLINIC, INVESTIGATION AND TREATMENT
SESSION
TV
Secretary: Jorge Leite
73
SESSION
TV
ABSTRACT ID
TITLE
SESSION
TV
ABSTRACT ID
A 32
STATUS AMONG MULTIPLE SCLEROSIS SUBTYPES
12:30 - 12:40
12:30-14:00
A 12
AND NEUROMYELITIS OPTICA
FATIGUE AND
A 99
COGNITION
A 100
Committee: Fernando
TV 05
A 139
Gracia, Elias Engelhart,
NEUROMYELITIS OPTICA: SEARCHING FOR A
COGNITIVE PATTERN
NEUROMYELITIS OPTICA: THE NEED TO
UNDERSTAND PATIENTS´ QUALITY OF LIFE
THE RELATIONSHIP BETWEEN FATIGUE AND GAIT IN
A 114
Fernanda Mendes
OF SWALLOWING IN PATIENTS WITH MULTIPLE
12:40 - 12:50
A 79
REVEALS PROTEIN LIPOXIDATIVE DAMAGE AS A
A 54
TV
12:30-14:00
A 55
TV 07
13:00 - 13:10
A 132
Cabrera, J Rivera Flores
13:10 - 13:20
A 134
Guimarães
A 144
TITLE
SESSION
12:30 - 12:40
12:30-14:00
A 138
12:40 - 12:50
TRATMENT
A 143
A 102
IGG ANTIBODY POSITIVITY IN A REHABILITATION
TV
THE DIAGNOSIS OF CIS, MS AND NMO SPECTRUM
TV 06
A5
Bento. Maria Cristina
del Negro Freitas e
ANTI-AQUAPORIN 4 ANTIBODY POSITIVE AND
PROGRESSIVE DISEASE
WITH NEUROMYELITIS OPTICA AND OPTIC SPINAL
Patricia Beatriz Marinho
MULTIPLE SCLEROSIS
Secretary: Luciana
LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS
Agostinho
A 79
REVEALS PROTEIN LIPOXIDATIVE DAMAGE AS A
ABSTRACT ID
TITLE
A 146
12:50 - 13:00
TV 08
13:00 - 13:10
THE PROFILE OF NATALIZUMAB ADVERSE EVENTS IN
12:30 - 12:40
MEASURE OF THERAPEUTIC RESPONSE & THE LONG TERM
12:40 - 12:50
Committee: Amilton
13:10 - 13:20
13:20 - 13:30
12:50 - 13:00
WITH MULTIPLE SCLEROSIS AFTER NATALIZUMAB
13:00 - 13:10
THE CERVICAL SPINAL CORD IN NEUROMYELITIS
A 134
OPTICA PATIENTS: A COMPARATIVE STUDY WITH
MULTIPLE SCLEROSIS USING DIFFUSION TENSOR
13:10 - 13:20
IMAGING
Lourenço
A 144
13:30 - 13:40
VECTRIMS CRITERIA
DISCONTINUATION: A CASE REPORT IN VENEZUELA.
e Alina Quevedo
Secretary: Giselle
TREATMENT FAILURE IN MULTIPLE SCLEROSIS:
REACTIVATION OF DISEASE ACTIVITY IN PATIENTS
A 116
Barreira, Patricio Abad
POTENTIAL PATHOGENIC MECHANISM.
A 39
13:20 - 13:30
IMPACT OF IMMUNOMODULATORY TREATMENT
FREQUENCY OF ANTI-AQP4 ANTIBODY IN PATIENTS
A 97
TRACT BASED SPATIAL STATISTICS (TBSS) IN THE
EVALUATION OF PATIENTS WITH NEUROMYELITIS OPTICA.
13:30 - 13:40
IN PERNAMBUCO, BRAZIL
Committee: Cleonice
13:10 - 13:20
THE SUSTAINED DISEASE ACTIVITY FREE STATUS AS
VALUE OF AQUAPORIN-4 ANTIBODY NMO-IGG AT
A 152
PATIENTS: A COMPARATIVE STUDY WITH MULTIPLE
HOSPITAL IN BRASILIA - BRASIL
COMPLEX
13:00 - 13:10
A 39
NMO AND NMO COMPLEX: FREQUENCY OF NMO-
SYNDROMES OF NMO
SCLEROSIS AND NEUROMYELITIS OPTICA: A
SCLEROSIS USING DIFFUSION TENSOR IMAGING
ABSTRACT ID
ANTI AQP4 IN
WHITE MATTER IN PATIENTS WITH MULTIPLE
THE CERVICAL SPINAL CORD IN NEUROMYELITIS OPTICA
13:30 - 13:40
4: THE EXPERIENCE OF CAPPEM-BH
12:50 - 13:00
COMPARATIVE STUDY WITH CONTROLS
and Maria Sheila Rocha
Secretary: Marcela
13:20 - 13:30
WHITE MATTER DAMAGE IN PATIENTS WITH
SWI PHASE VALUES OF THE WHOLE GRAY AND
Committee: José
NEUROMYELITIS OPTICA AND ANTIBODY ANTIAQUAPORIN
12:40 - 12:50
NEUROMYELITIS OPTICA AND MULTIPLE SCLEROSIS
A 39
A 93
RESONANCE IMAGING IN THE ASSESSMENT OF
EVALUATION OF MICROSTRUCTURAL BRAIN
POTENTIAL PATHOGENIC MECHANISM.
SESSION
12:30 - 12:40
PATIENTS WITH NEUROMYELITIS OPTICA
LIPIDOME ANALYSIS IN MULTIPLE SCLEROSIS
Deslandes
WITH CLINICALLY ISOLATED SYNDROME AND
RESTING-STATE FUNCTIONAL MAGNETIC
RESONANCE AND NMO
12:50 - 13:00
SCLEROSIS: PRELIMINARY ANALYSIS
Secretary: Mariana
SCLEROSIS PATIENTS: A COMPARISON STUDY
NEUROMYELITIS OPTICA
PROFILE OF THE ORAL AND PHARYNGEAL PHASES
Patricio Abad and Maria
BRAIN ATROPHY EVALUATION IN MULTIPLE
COMPARISON OF FATIGUE AND FUNCTIONAL
12:30-14:00
TITLE
A 39
TRACT BASED SPATIAL STATISTICS (TBSS) IN THE
EVALUATION OF PATIENTS WITH NEUROMYELITIS OPTICA.
13:20 - 13:30
13:30 - 13:40
The abstracts of the 7th Congress of LACTRIMS-RIO 2012 are
published in Multiple Sclerosis Journal, 2012. 18 (55)
74
75
76
77
BETAFERON® - BETAINTERFERONA 1B - REG. MS – 1.0020.0080
INDICAÇÕES - PACIENTES COM UM ÚNICO EVENTO CLÍNICO SUGESTIVO DE ESCLEROSE MÚLTIPLA (SÍNDROME CLINICAMENTE ISOLADA) - PARA RETARDAR A PROGRESSÃO À ESCLEROSE MÚLTIPLA DEFINIDA. ESCLEROSE MÚLTIPLA RECORRENTE-REMITENTE (EMRR). ESCLEROSE MÚLTIPLA SECUNDÁRIA
PROGRESSIVA (EMSP). CONTRAINDICAÇÕES: BETAFERON® (BETAINTERFERONA 1B) É CONTRAINDICADO EM PACIENTES COM HISTÓRIA DE HIPERSENSIBILIDADE À BETAINTERFERONA NATURAL OU RECOMBINANTE OU A QUALQUER EXCIPIENTE DO PRODUTO. CUIDADOS E ADVERTÊNCIAS: A ADMINISTRAÇÃO
DE CITOCINAS AOS PACIENTES COM GAMOPATIA MONOCLONAL PRÉ-EXISTENTE FOI ASSOCIADA COM O DESENVOLVIMENTO DE SÍNDROME DE EXTRAVASAMENTO CAPILAR SISTÊMICO, COM SINTOMAS QUE SE ASSEMELHAM AO CHOQUE E EVOLUÇÃO FATAL. PACIENTES QUE VENHAM A SER TRATADOS COM
BETAFERON® (BETAINTERFERONA 1B) DEVEM SER INFORMADOS QUE PODEM OCORRER DISTÚRBIOS DEPRESSIVOS E IDÉIAS SUICIDAS COMO EFEITOS SECUNDÁRIOS DO TRATAMENTO, DEVENDO COMUNICAR IMEDIATAMENTE AO MÉDICO A OCORRÊNCIA DESTES SINTOMAS. O MEDICAMENTO DEVE SER ADMINISTRADO COM CUIDADO AOS PACIENTES COM HISTÓRIA OU DIAGNÓSTICO DE DISTÚRBIOS DEPRESSIVOS OU COM IDÉIAS SUICIDAS. ESTE PRODUTO CONTÉM ALBUMINA HUMANA E, PORTANTO, EXISTE UM RISCO EXTREMAMENTE REMOTO PARA A TRANSMISSÃO DE DOENÇAS VIRAIS. O RISCO TEÓRICO PARA
A TRANSMISSÃO DA DOENÇA DE CREUTZFELD-JACOB É CONSIDERADO TAMBÉM EXTREMAMENTE REMOTO. ALÉM DOS TESTES DE LABORATÓRIO REQUERIDOS NORMALMENTE PARA O MONITORAMENTO DE PACIENTES COM ESCLEROSE MÚLTIPLA, É RECOMENDADA A REALIZAÇÃO DOS SEGUINTES TESTES,
ANTES DO INÍCIO E NO PERÍODO APÓS A INTRODUÇÃO DO TRATAMENTO EM INTERVALOS REGULARES, E DEPOIS PERIODICAMENTE NA AUSÊNCIA DE SINTOMAS CLÍNICOS: HEMOGRAMA COMPLETO E LEUCOGRAMA DIFERENCIAL, CONTAGEM DE PLAQUETAS E BIOQUÍMICA DO SANGUE INCLUINDO TESTES DE
FUNÇÃO HEPÁTICA ( TGO, TGP E GT). SÃO RECOMENDADOS TESTES PERIÓDICOS DA FUNÇÃO TIREOIDIANA NOS PACIENTES COM HISTÓRIA DE DISFUNÇÃO DA TIRÓIDE OU COM INDICAÇÃO CLÍNICA. BETAFERON® (BETAINTERFERONA 1B) DEVE SER ADMINISTRADO COM CAUTELA EM PACIENTES COM HISTÓRIA
DE CONVULSÕES. DEVE SER UTILIZADO COM CUIDADO EM PACIENTES COM DISTÚRBIOS CARDÍACOS PRÉ-EXISTENTES. MULHERES EM IDADE FÉRTIL DEVEM ADOTAR MEDIDAS CONTRACEPTIVAS APROPRIADAS. NÃO É CONHECIDO SE BETAFERON® (BETAINTERFERONA 1B) PODE CAUSAR LESÃO FETAL QUANDO
ADMINISTRADO ÀS MULHERES GRÁVIDAS OU SE PODE AFETAR A CAPACIDADE REPRODUTIVA HUMANA. DEVIDO À OCORRÊNCIA POTENCIAL DE REAÇÕES ADVERSAS GRAVES NOS LACTENTES, DEVE-SE DECIDIR ENTRE A INTERRUPÇÃO DA AMAMENTAÇÃO OU DO TRATAMENTO COM BETAFERON® (BETAINTERFERONA 1B). EM PACIENTES SUSCETÍVEIS, OS EFEITOS ADVERSOS RELACIONADOS AO SNC ASSOCIADOS COM O USO DE BETAFERON® (BETAINTERFERONA 1B) PODEM INFLUENCIAR A HABILIDADE DE DIRIGIR E UTILIZAR MÁQUINAS. INTERAÇÃO MEDICAMENTOSA: NÃO FORAM REALIZADOS ESTUDOS SISTEMATIZADOS DE INTERAÇÃO DE BETAFERON® (BETAINTERFERONA 1B) COM OUTROS MEDICAMENTOS. FOI RELATADO QUE AS INTERFERONAS REDUZEM A ATIVIDADE DE ENZIMAS HEPÁTICAS DEPENDENTES DO CITOCROMO P450 EM SERES HUMANOS E NOS ANIMAIS. DEVE-SE TER CAUTELA QUANDO BETAFERON®
(BETAINTERFERONA 1B) É ADMINISTRADO EM COMBINAÇÃO COM MEDICAMENTOS QUE APRESENTAM ESTREITA MARGEM TERAPÊUTICA E SÃO LARGAMENTE DEPENDENTES DO SISTEMA HEPÁTICO CITOCROMO P450 PARA A SUA DEPURAÇÃO. DEVE-SE TER CUIDADO NA ADMINISTRAÇÃO CONCOMITANTE DE
MEDICAMENTOS QUE TENHAM EFEITO SOBRE O SISTEMA HEMATOPOIÉTICO. REAÇÕES ADVERSAS: FREQÜENTEMENTE FORAM OBSERVADOS SINTOMAS SEMELHANTES AOS GRIPAIS (FEBRE, CALAFRIOS, ARTRALGIA, INDISPOSIÇÃO GERAL, SUDORESE, CEFALÉIA OU MIALGIA). A OCORRÊNCIA DESTES SINTOMAS
DIMINUIU COM O PASSAR DO TEMPO. DE MODO GERAL, RECOMENDA-SE A TITULAÇÃO DA DOSE NO INÍCIO DO TRATAMENTO, A FIM DE AUMENTAR A TOLERABILIDADE AO BETAFERON® (BETAINTERFERONA 1B) (VER ITEM “POSOLOGIA”). SINTOMAS SEMELHANTES AOS GRIPAIS TAMBÉM PODEM SER REDUZIDOS
COM A ADMINISTRAÇÃO DE UM ANTIINFLAMATÓRIO NÃO ESTEROIDAL. REAÇÕES NO LOCAL DE INJEÇÃO OCORRERAM FREQÜENTEMENTE APÓS A ADMINISTRAÇÃO DE BETAFERON® (BETAINTERFERONA 1B). VERMELHIDÃO, INCHAÇO, ALTERAÇÃO DE COR, INFLAMAÇÃO, DOR, HIPERSENSIBILIDADE, NECROSE E
REAÇÕES NÃO-ESPECÍFICAS FORAM ASSOCIADAS, DE MODO SIGNIFICATIVO, AO TRATAMENTO COM 0,25 MG (8 MILHÕES DE UI) DE BETAFERON® (BETAINTERFERONA 1B). A NECROSE PODE SER EXTENSA E PODE ENVOLVER A FÁSCIA MUSCULAR, ASSIM COMO TECIDO ADIPOSO E, PORTANTO, PODE RESULTAR EM
FORMAÇÃO DE CICATRIZ. OCASIONALMENTE SÃO NECESSÁRIOS DEBRIDAMENTO E, MENOS FREQÜENTEMENTE, ENXERTO DE PELE. DE MODO GERAL, A INCIDÊNCIA DE REAÇÕES NO LOCAL DE INJEÇÃO DIMINUIU COM O PASSAR DO TEMPO. O TRATAMENTO COM BETAFERON® PODE ASSOCIAR-SE COM ALTERAÇÕES HEMATOLÓGICAS (ANEMIA, LEUCOPENIA E TROMBOCITOPENIA) E ALTERAÇÕES HEPATOBILIARES (ALTERAÇÕES DAS ENZIMAS ALANINA AMINOTRANSFERASE E ASPARTATO AMINOTRANSFERASE). ASSIM COMO PARA OUTRAS BETAINTERFERONAS, FORAM RELATADOS CASOS RAROS DE LESÃO HEPÁTICA
GRAVE, INCLUINDO FALÊNCIA HEPÁTICA, EM PACIENTES TRATADOS COM BETAFERON® (BETAINTERFERONA 1B). OS EVENTOS MAIS GRAVES FREQÜENTEMENTE OCORRERAM EM PACIENTES QUE UTILIZAVAM OUTROS FÁRMACOS OU SUBSTÂNCIAS HEPATOTÓXICAS OU NA PRESENÇA DE CONDIÇÕES MÉDICAS
GRAVES CONCOMITANTES (POR EXEMPLO: DOENÇA MALIGNA COM METÁSTASE, INFECÇÃO GRAVE E SEPTICEMIA, ABUSO DE BEBIDAS ALCOÓLICAS). RARAMENTE O TRATAMENTO COM BETAFERON® FOI ASSOCIADO À DISFUNÇÃO DA TIREÓIDE (HIPO OU HIPERTIROIDISMO); ANOREXIA E CONVULSÃO. ALOPECIA,
PRURIDO, URTICÁRIA, MIALGIAS OCORRERAM POUCO FREQUENTEMENTE DURANTE O TRATAMENTO COM BETAFERON®. RARAMENTE OBSERVARAM-SE ALTERAÇÕES MENSTRUAIS E PANCREATITE AGUDA POR HIPERTRIGLICERIDEMIA. POSOLOGIA: O TRATAMENTO COM BETAFERON® (BETAINTERFERONA 1B)
DEVE SER INICIADO COM A SUPERVISÃO DE UM MÉDICO EXPERIENTE NO TRATAMENTO DA ESCLEROSE MÚLTIPLA. A DOSE RECOMENDADA DE BETAFERON® (BETAINTERFERONA 1B) É DE 0,25 MG (8 MILHÕES DE UI), CONTIDA EM 1 ML DA SOLUÇÃO RECONSTITUÍDA (VER, EM ANEXO, INSTRUÇÕES DETALHADAS
PARA PREPARAÇÃO E ADMINISTRAÇÃO), DEVENDO SER INJETADA POR VIA SUBCUTÂNEA, EM DIAS ALTERNADOS. GERALMENTE, A TITULAÇÃO DA DOSE É RECOMENDADA NO INÍCIO DO TRATAMENTO. OS PACIENTES DEVEM INICIAR O TRATAMENTO COM 0,0625 MG (0,25 ML), POR VIA SUBCUTÂNEA, EM DIAS
ALTERNADOS, E AUMENTAR A DOSE GRADUALMENTE PARA 0,25 MG (1,0 ML), EM DIAS ALTERNADOS. O PERÍODO DE TITULAÇÃO PODE SER AJUSTADO DE ACORDO COM A TOLERABILIDADE INDIVIDUAL. VENDA SOB PRESCRIÇÃO MÉDICA.
VENDAS SOB PRESCRIÇÃO MÉDICA. BETAFERON NÃO DEVE SER USADO EM PACIENTES CARDIOPATAS. BETAFERON PODE APRESENTAR
INTERAÇÃO MEDICAMENTOSA COM BEBIDAS ALCÓOLICAS. BETAFERON PODE INFLUENCIAR A HABILIDADE DE DIRIGIR E UTILIZAR MÁQUINAS.
L.BR.SM.2012-11-19.0365
Material destinado exclusivamente à classe médica.
Para mais informações consulte a bula do produto ou a BAYER S.A produtos farmacêuticos. Rua Domingos Jorge, 1100 - São Paulo - SP - CEP: 04779-900
www.bayerpharma.com.br
78
79
SPONSORS
GOLD
SILVER
BRONZE
80

clique aqui para visualizar o programa final.

Transcrição

Documentos relacionados

A Esclerose Lateral Amiotrófica e a Fisioterapia Motora Fabrícia A

PORTARIA Nº 1.323, DE 25 DE NOVEMBRO DE

Brokeback Mountain feminino: Beyonce e Eva Longoria (O Popular)

Protocolo Clínico e Diretrizes Terapêuticas

Revista americana confirma romance gay de atriz

Almancil Area Price: 620 000,00€ CHARMING 4 BEDROOM VILLA

Exercícios de Força na Esclerose Lateral Amiotrófica (ELA

Artigo: Importância do atendimento multidisciplinar a pacientes com

Almancil Area Price: 2 995 000,00€ MAGNIFICENT 6 BEDROOM

Two nights in a double room at Hotel Martinhal

convite